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Migraine is now perceived to be a complex neurovascular disorder prevalent in a specific 
age group of young to middle age population. Although the underlying cause of this 
condition is still not clearly understood; current scientific thinking suggests the 
involvement of both the serotonergic and dopaminergic pathways. An attempt is made 
through this research to throw some light on the pathogenesis of this disorder by exploring 
the role of neurotransmitters, serotonin (5-HT) & dopamine (DA), and the possible 
activation of their pathways by molecules that mimic them structurally at their receptors. 
We have explored in-silico, the possibility of anti-migraine drugs mimicking 5-HT and how 
they interact with 5-HT receptors; by obtaining their docking scores and glide scores, which 
are indicative of these drugs mimicking 5-HT at 5-HTRs and allowing a successful 
interaction at specific receptor conformation.  There is also a possibility of similar 
molecular mimicry from other sources such as specific foods resulting in dyshomeostasis of 
important biochemicals such as 5-HT or DA in our body system. We hypothesise that 5-HT 
or DA dyshomeostasis together with other genetically predisposed contributors and 
vasoactive biochemicals can sensitise or activate the brain centres to trigger migraine 
response. Anti-migraine drugs which can activate these monoaminergic receptors are 
doing so because they are able to mimic their natural ligands, and by doing so they might 
possibly correct this 5-HT or DA dyshomeostasis partially, which is subject to its availability 
in the affected CNS region. Structural analogy of the anti-migraine drugs to the 
neurotransmitters, makes it a good reason to explore their role in correcting such 
underlying dyshomeostasis, which might explain their drug efficacy and thus hinting at a 
scope to develop a targeted treatment for migraine in the future. We hope this research 
work on the potential drug analogy to neurotransmitters, helps contribute to the 









             Chapter 1 Introduction 
 





1 Introduction  
1.1 Background  
 
Migraine is a primary episodic headache disorder characterised by neurological, 
gastrointestinal, and autonomic changes (1). The word migraine is derived from the Greek 
word hemicrania, first used by Galen in 200 AD; ‘Hemi’ means half in Greek, and ‘Crania’ 
means skull, as migraine is characterised by pain in one half of the head.  ‘Hemicrania’ over 
the years transformed into ‘migraine’ as we know today. 
 
The unique symptoms of migraine distinguish the disorder from other manifestations of 
headache.  For example, migraine is characterised by neurobiological events such as 
blurred vision, a wave of cortical neuronal activity depression spreading during a migraine 
with aura (usually visual, however can be other sensory or verbal disturbances) and 
hypersensitivity to sensory stimuli (e.g., sound, light, smell).  Indeed, migraine sometimes is 
not associated with headache per se, but manifests as aura alone.  
 
There are a multitude of theories among scientists to explain the aetiology of migraine. 
However, it is widely accepted that certain triggers contribute to the onset of migraine, 
such as decreased serum oestrogen levels (e.g., post ovulation (2)),  stress factors (e.g., 
anxiety (2, 3)), or certain food cravings (e.g., cheese, coffee, chocolate, peanut butter, red 
wine (4, 5)). Components of these foods (e.g. caffeine in coffee) are believed to initiate the 
onset of migraine by triggering symptoms, for example, cortical spreading depression (CSD) 
(2, 4, 5). CSD involves a sudden change in the ion homeostasis of cortical neurons and is 
characterized by severe spreading of neuronal excitation followed by an extended period 
of neuronal depression (2) (also see section 1.4.10). It is possible that this neuronal 
excitation phase leads to food cravings to redress a biochemical imbalance.   
 
Migraine is now considered to be a complex neurovascular primary headache disorder (as 
defined by the International Classification of Headache Disorders (6)), common among  
young to middle age population. Interestingly, migraine is more commonly reported 





among females than males, during their lifetime: prevalence increases in females rapidly 
after puberty while the same rapid increase is not seen in males (7, 8). This increased 
prevalence of migraine continues after puberty in males and females, up to 40 years of age 
then declines; however, before puberty the prevalence is similar in both genders (7, 8). 
Stable serum oestrogen levels have a protective effect against the recurrence of migraine 
in women. For example, the hyper-oestrogenic state during pregnancy or during lactation  
is associated with a decreased incidence or improved symptoms of migraine (2).  
Migraine can be highly debilitating and seriously impact the wellbeing, quality of life, and 
the economic status due to increased healthcare costs, reduced income due to missed 
work days or other missed earning opportunities. 
 
The above impacts on life are difficult to ameliorate because there is no simple cure or 
100% effective treatment yet available for migraine.  For a long time, migraine has been 
treated symptomatically. A complete cure is likely a long way off, as the root cause is still 
not completely understood. With advances in our understanding of the biochemistry 
underpinning migraine, we might expect developments in the treatment options and 
improved outcomes for migraine sufferers.     
     
Most of us have suffered headache at some point in our lives. Some migraine sufferers 
simply get used to the fact that they cannot stop migraine from recurring and do not visit 
their doctor thus receiving no formal treatment.  For this reason, the full extent of migraine 
occurrence is probably not known for the general population.  Despite all this, headache 
(including migraine) remains the 3rd most common cause of missed work, and has a 




Since the dawn of human civilisation migraine is known to have existed: some well-known 
migraine sufferers from ancient history include Julius Caesar, Charles Darwin, Sigmund 
Freud and  Napoleon to name a few (8). Though not many evidences of treating migraine 
during the ancient era, a surgical intervention called the trepanation procedure has been 





practised since 7000 BC as a treatment for migraine. In this procedure, the skull is 
perforated with an instrument. Trepanation may have been done to release demons and 
evil spirits, that were believed to have caused headaches such as migraine, during this 
period (8). There is evidence of Egyptian prescriptions called the Ebers Papyrus, written in 
1200 BC, which describes migraine symptoms (8). Hippocrates described migraine with 
aura in 400 BC (8, 9) and believed vapours arising from the stomach caused the headache. 
However, it was also believed by some to be a punishment from God (8, 9). By the 13th 
century, migraine treatments were diverse, from plant-derived analgesics such as opium to 
simple vinegar. By the 19th century Charles Darwin suggested centrifugation as a means of 
treating migraine, because he believed brain vasodilation was the cause of migraine and 
believed that centrifugal force would force blood out of brain and relieve the symptoms (2, 
8, 9).  
 
The first book on migraine was written in 1873 by Edward Liveing, where he proposed a 
neuronal theory of migraine, describing it as disturbances in the autonomic nervous system 
(8, 9). Towards the end of the 19th century Sir William Gowers recommended Indian hemp 
(marijuana) as a treatment for migraine. In 1938 John Graham and Harold Wolff 
demonstrated for the first time that ergotamine, produced by the ergot fungus (Claviceps 
purpurea), was an effective treatment for migraine because it resulted in vasoconstriction 
– this also supported the vascular theory of migraine (8, 10). By 1943 dihydroergotamine 
(DHE) was synthesised by Stoll and Hoffman and was first used commercially for migraine 
treatment (10): synthetic ergotamines are still used extensively in the treatment of 
migraine even today.  
 
As of today, migraine treatment is partly determined by the symptoms and the 
mechanisms thought to be responsible for the symptoms of migraine.  There were two 
theories hotly debated: the vascular hypothesis proposed that migraine headaches were 
due to vasodilation of the extracranial blood vessels, and the neurogenic theory proposed 
vasoconstriction of  the intracranial blood vessels resulting in neurological events (10). By 
the late 20th century various schools of thought challenged both the vascular and 
neurogenic theories. In 1981 a study by Olsen measured oligemic (reduced total blood 





volume in this case in a localised region) episodes in which a wave of reduced blood flow 
originating from the occipital lobe spreads across to the half region of the brain during the 
episodes of migraine.  This suggested that reduced blood flow was not due to 
vasoconstriction, but rather due to vasoactive neurotransmitters causing vasodilation (11). 
This sea change in understanding the aetiology of migraine led to the evolution of 
treatment modalities. 
 
Sumatriptan, which is commonly used to treat migraine nowadays, does not have analgesic 
properties as such; however, when used in migraine, it relieves symptoms of pain (10).  A 
breakthrough in understanding of triptan’s mode of action (MOA) in migraine came out of 
a sumatriptan study published in 1991 (12). In this study, middle cerebral artery (MCA) 
flow velocities were measured: it was found that during migraine attacks, MCA flow 
velocity was reduced due to a 20% increase in artery diameter (i.e. dilation, often termed 
distended arteries).  Sumatriptan improved the flow within 30 min and the dilatation was 
reversed. Hence, it was believed that migraine headache were due to large intracranial 
arterial dilatation and that sumatriptan acted predominantly on distended arteries during 
migraine attacks (10, 12). 
 
 Current concepts and pathophysiology of migraine  
 
Although the underlying cause of migraine is still not clearly understood due to varying 
theories and concepts; current scientific thinking suggests the involvement of serotonergic, 
noradrenergic and dopaminergic pathways in the central nervous system (CNS) (1, 13-18). 
These neurotransmitters are key to the activation of the trigeminal nervous system, which 
is thought to be the cause behind neurogenic vascular events such as CSD and 
hyperactivation of the sensory stimuli.   
 
The migraine attack progresses through different stages in some patients, which include 
aura as well as changes in cortical function, blood flow, and neurovascular events. The aura 
phase overlaps with the headache phase, which is associated with further changes in blood 
flow, activation of the brainstem, thalamus, hypothalamus, and cortex (14, 19). 





Neurotransmitter receptors such as serotonin receptors (5-HTRs), vasoactive biochemicals 
such as Nitric Oxide (NO), vasoactive neuropeptides such as calcitonin gene-related 
peptide (CGRP), and other biochemicals such as pituitary adenylate cyclase-activating 
polypeptide, and prostanoids have been implicated in developing migraine based on 
therapeutic and triggered migraine studies (18). Hence the neurovascular hypothesis is a 
good approach to explain various events associated with a migraine attack, and to 
understand the subsequent amelioration of pain obtained with anti-migraine drugs; for 
example, sumatriptan produces cranial vasoconstriction and inhibition of the trigeminal 
nervous system demonstrated in experiments in rats and guinea pig (13, 20).  
 
Based on the clinical features of migraine, there are 4 known stages. Each stage has 
specific symptoms, and patients may experience all or some of the symptoms (8, 13). 
These stages are: 
 
• Prodromal phase:  Symptoms appear a few hours or a day before the actual onset of 
headache. Symptoms involve feelings of sluggishness, depression, craving for certain 
foods, increased appetite, etc. This stage can also be considered as a trigger phase 
due to mixed behavioural and feeling changes. Some think that certain foods can act 
as a trigger due to mixed food cravings experienced during this stage, and some 
think that environmental factors contribute to mood changes and can act as a trigger 
as well. 
• Aura phase: A few migraineurs (i.e. a migraine sufferer) experience aura with or 
without headache. There are many forms of aura; the most common kind is visual 
aura such as scintillating scotoma characterised by disturbed one half of the vision 
with expanding bright light flashes. The other kind of aura is sensory aura 
characterised by tingling or numbness sensations on the lips or in one hand. Other 
auras involve the inability to speak, hallucination of abnormal smell, weakness on 
one side of the body and visual distortions called ‘Alice in Wonderland syndrome’ 
based on the writer Lewis Carroll’s imagery from his novel of the same name: Carroll 
could have been describing his own migraine aura experiences in his story book (8).  





• Aphasic aura (i.e. difficulty speaking, reading and writing) and motor aura (i.e. 
difficulty moving) are also experienced by some. 
• Attack phase: This is the actual headache phase characterised by pulsating, 
throbbing or severe pain on one side of the head, along with nausea and/or vomiting 
and hypersensitivity to light and sound (8). Some experience swelling of their 
fingertips, difficulty with mental alertness, and memory issues. 
• Postdromal phase: This is the end phase of migraine; it manifests as tiredness (this is 
often regarded as a relief), depression, and, for some, it is a relief phase because the 
debilitating headache is over. 
 
 Migraine’s link to specific foods and the structural analogy of dietary amino acids to 
neurotransmitters in migraine 
 
The onset of migraine can be linked to specific foods, which are also known to be the 
sources of certain dietary amino acids (AAs), such as the biogenic amino form of tyrosine 
known as tyramine (Fig. 1.1) and tryptophan which is a precursor to serotonin(4, 5, 21-25). 
Interestingly, tyramine has a structural analogy to certain neurotransmitters such as DA 
and NE (Fig. 1.2), as these neurotransmitters share a structural commonality with 
tyramine’s molecular structure (Fig. 1.2) (26, 27). Tyramine is found in cheese, chocolate 
and wine (Fig. 1.1), which many migraineurs report having experienced severe food 
cravings for, especially during the prodromal phase. However, some researchers believe 
that these foods are not migraine triggers (8). This structural analogy between AAs and 
neurotransmitters could mean these AAs have the potential to mimic their ‘lookalike’ 
neurotransmitters; for example, in the CNS, these compounds may behave like their 
lookalike neurotransmitters if they are able to cross the blood brain barrier (BBB). There 
are also non-food migraine triggers relating to specific situations (e.g., anxiety, depression, 
stress) or specific environmental conditions (e.g., temperature variations) etc. (26, 28).   
 





Tyramine (Fig. 1.1 & 1.2) is a naturally occurring biogenic monoamine found in cheese and 
chocolate; it is derived from the amino acid tyrosine via decarboxylation by certain 
microorganisms in the gut or during the fermentation process of foods (29-31). The striking 
structural similarity of tyramine (Figure 1.2) to NE & DA could explain why migraine 
patients relate their onset of symptoms to these specific foods.  Hence, it is possible that 
tyramine substitutes for either NE or DA in the synaptic system, perhaps initiating a 
neurotransmission which could be the basis of the onset of migraine symptoms (Fig. 1.8; 
see also Discussion Section 3.2.1). The presence of tyramine in the human brain suggests 
that they are able to cross the BBB (perhaps via the G protein, trace amine-associated 
receptor 1 (TAAR1) (32)) and, therefore, one can assume that it can interfere with DA and 
NE-mediated neurotransmission due to their molecular structural analogy (Fig. 1.2 & 1.9).  
On the other hand, there is a possibility that tyramine might be formed by decarboxylation 
of tyrosine in the brain itself rather than crossing the BBB (Fig. 1.3) and therefore besides 
food sources, tyramine can be formed in the brain itself.  The distinction between these 
two possible sources of tyramine’s presence in the brain is not understood (See Discussion, 
Section 3.2.1). TAAR1 is found in the brain, peripheral tissues, and other internal organs 
including kidneys and are known to have high affinity for tyramine (32). Hence TAAR1 can 
be considered as a carrier protein of tyramine. Tyramine is metabolized by monoamine 
oxidase (MAO) enzyme, however its metabolism can be compromised in the presence of 
agents such as monoamine oxidase inhibitors (MAOIs). When foods high in tyramine are 
ingested along with MAOIs, a hypertensive crisis can result, as it can displace stored 
monoamines, such as dopamine from the neuronal vesicles (32). Thus, a large dietary 
intake of tyramine (or a dietary intake of tyramine while taking MAO inhibitors) can result 
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 Figure 1.1 Dietary sources of tryptophan, serotonin, and Tyramine.Tryptophan is an essential amino acid, 
precursor to serotonin (neurotransmitter). Tryptamine is structurally analogous to both serotonin and 
tryptophan, and similarly tyramine to DA & NE (Figure 1.2). Both tryptamine and tyramine are known to be 
found in trace amounts in the brain of mammals; however, whether they can cross the BBB is still 
questionable.  Tyramine is known to have high affinity to TAAR1 receptors in brain (32), which might aid in its 
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Figure 1.2 Tyramine (A), noradrenalin (B), dopamine (C) and the three molecules superimposed (D) to show 
their structural analogies. 
 
an increase in systolic blood pressure of 30 mmHg or more (32, 33). The displacement of 
neurotransmitters other than dopamine, such as norepinephrine (noradrenaline) from 
neuronal storage vesicles by mimics such as tyramine can also lead to vasoconstriction, 
increased heart rate and high blood pressure due to a counter pressor response (26, 28, 
33). Such a counter pressor response due to the displacement of monoamine 
neurotransmitters can be understood by the complexity involved in the neurotransmission 
processes. Nerve terminals involving postsynaptic receptors, pre-synaptic regulatory 
receptors and transporters as shown in Fig. 1.9 play a crucial role in this transmission 
mechanism by maintaining a constant or balanced concentration (i.e. homeostasis) of 
neurotransmitters in the synaptic region as well as in the neuronal vesicles.  Maintaining 
this constant or balanced concentration of neurotransmitters in the synaptic cleft, can be 
compared to a buffer solution where the pH is maintained even when there are 
fluctuations in the levels of H+ ions due to small additions of acids or bases. Similarly, the 
neuronal vesicles, pre & post synaptic receptors, neurotransmitter degrading enzymes and 
transporter proteins together give the effect of a buffering mechanism where a balanced 
level of neurotransmitters at the synaptic cleft is maintained which in turn contributes to 
the homeostasis of the neurotransmitter level at the synapse and the neuronal vesicles.   
 
Disturbances in this homeostasis (dyshomeostasis) can have significant repercussions, and 
the mechanisms by which it counter acts to this disturbance is still not clearly understood. 





In the absence of neurotransmitter availability in neuronal vesicles, molecular mimics such 
as tyramine may replace DA neurotransmitters or there could be situation of excess 
molecules contributing to disturbances in the homeostasis at the synaptic cleft. In such 
situation, there is a potential to generate a counter response, hence we hypothesise that 
migraine might be part of such counter response complications to dyshomeostasis. 
It is interesting to note that DA, NE and 5-HT, are known to be involved in the 
pathophysiology and treatment of various neuro disorders. These neurotransmitters are 
constantly being released into the synapses, to regulate various biological processes in 
CNS, which is being currently explored extensively by the scientific community. Any change 
in their systemic level can have reciprocal response or modulatory response between these 
neurotransmitter systems, for example, an antagonistic effect on the serotonergic system 
by certain molecules can have an enhanced firing rate of the dopaminergic system and 
noradrenergic system and vice versa (21). Therefore, we may assume that, molecules 
selectively targeting one system-specific receptor can indirectly modify the neuronal firing 
activity of the other two systems. 
 
Figure 1.3  Tyrosine AA undergoes decarboxylation in the gut to form tyramine 
 
 The Prevalence of Migraine  
 
Based on the Global Burden of Disease Study 2010 & 2015, the International Headache 
Society (IHS), stated that migraine is ranked as the third most prevalent and disabling 
disorder worldwide in both males and females under the age of 50 years (6). Many 
epidemiological studies have documented the impact of migraine from a social, financial 
and personal perspective and its significant prevalence worldwide. Globally, 46% of the 
adult population is affected by active headache disorder including migraine in general, of 





which 42% reported tension-type headache, 11% migraine, and 3% chronic daily headache 
(34). Generally, the prevalence of migraine is higher among females compared to males. In 
a study based on the US population, migraine was reported in 18.2% of females compared 
to only 6.5% in males (i.e., approx. 3 times more common in females than males) (35). 
Migraine as mentioned before is often reported from the beginning of adolescence as the 
hormone level seems to have an influence on the incidence by rapidly increasing it up to 40 
years of age then declines probably due to reaching the menopausal stage (35, 36) In 
females, thus migraine attacks have been linked to hormone levels; for example, in some 
studies migraine was associated with reduced incidence during pregnancy (2, 37). In the 
USA, the prevalence of migraine is reported to be approx. 13% of the general population as 
afflicted with the disorder (35). Migraine can severely impact a person’s quality of life, the 
capacity to contribute at work, or study.  These impacts can significantly affect a sufferer’s 
capability, and because migraine is likely to have significantly underdiagnosed and 
undertreated, the overall social and economic impacts are probably greater than what is 
expected. The economic impact is also considerable due to missed work days and the high 
cost of treatment. 
 
Typical symptoms of migraine are headache with or without aura, nausea, vomiting, 
blurred vision, light headedness sometimes followed by fainting etc with a frequency 
ranging from once a year to once a week in affected people in general (35).  
 Data from another study based on the American Migraine Prevalence and Prevention 
Study, which was conducted on a mailed survey sent out to 120,000 US families, reported 
the incidence of migraine was maximum between the ages of 20 and 24 years old in 
women and 15 and 19 years old in men (36). The most interesting findings from the above 
study were; overall incidence reported was more than double among women (43%) than 
with men (18%) and the median age for the onset of migraine among women was 25 years 
and 24 years for men. Four of every 10 women and two of every 10 men will contract 
migraine in their lifetime, most before the age of 35 years of age (36).  
 
 





1.2 Migraine and its treatment 
Migraine is classified into many different types as per the International Classification of 
Headache Disorders 3rd edition (ICHD-3), published by International Headache Society 
(IHS). IHS is a registered charity organisation founded by committed professionals globally 
and is based in the UK. The next section will highlight the types of migraine for diagnostic 
purposes and the different treatment options of migraine.  
 Types of migraine  
Though there are many types of migraine (Fig.1.4), two categories are most commonly 
used, migraine without aura and migraine with aura. An example of a subtype of migraine 
with aura is retinal migraine. As the name suggests it affects the retina of the eye causing 
visual disturbances including blindness usually accompanied by headache. A subtype of 
complications of migraine, known as migrainous infarction, occurs in migraine with aura 
accompanied by ischaemic brain lesions diagnosed with neuroimaging scans. In the case of 
hemiplegic migraine, aura is accompanied by fully reversible motor weakness symptoms 
along with visual, sensory and/or speech or language symptoms (6).  
 
Migraine without aura is characterized by headache with specific symptoms, such as with 
nausea and/or photophobia and phonophobia while migraine with aura is primarily 
characterized by short term neurological symptoms affecting a specific region of the brain 
that usually precedes or sometimes accompanies the headache. Some patients experience 
varying symptoms as they pass through the different phases of migraine (see section 1.1.3) 
such as prodromal and postdromal phase, which include hyperactivity, hypoactivity, 
depression, nausea, vomiting, photosensitivity, phonophobia, cravings for specific foods, 
repetitive yawning, neck stiffness etc. Generally, the diagnosis for migraine headache is 
made based on the ICHD -3 criteria and excluding secondary headache disorders, where a 
pre-existing condition such as a tumour is the cause for headache (6, 7, 38). Though there 
are different classes of migraine for diagnostic purposes, migraine is perceived by people in 
general as a form of headache disorder with unique symptoms, slightly different from the 
ordinary headaches for the public as not much is known about the disorder due to lack of  
 






Figure 1.4 Different classes of migraine (table adapted from: https://www.ichd-3.org/1-migraine) 
 Listing of different classes of Migraine for diagnosis purpose as per the International classification of 







1.1 Migraine without aura
1.2 Migraine with aura
1.2.1 Migraine with typical 
aura
1.2.1.1 Typical aura with headache
1.2.1.2 Typical aura without 
headache
1.2.2 Migraine with brainstem 
aura
1.2.3 Hemiplegic migraine
1.2.3.1 Familial hemiplegic 
migraine (FHM)
1.2.3.1.1 Familial hemiplegic 
migraine type 1 (FHM1)
1.2.3.1.2 Familial hemiplegic 
migraine type 2 (FHM2)
1.2.3.1.3 Familial hemiplegic 
migraine type 3 (FHM3)
1.2.3.1.4 Familial hemiplegic 
migraine, other loci




1.4 Complications of migraine
1.4.1 Status migrainosus
1.4.2 Persistent aura without 
infarction
1.4.3 Migrainous infarction
1.4.4 Migraine aura-triggered 
seizure
1.5 Probable migraine
1.5.1 Probable migraine without 
aura
1.5.2 Probable migraine with aura
1.6 Episodic syndromes that may be associated with 
migraine
1.6.1 Recurrent gastrointestinal 
disturbance
1.6.1.1 Cyclical vomiting syndrome
1.6.1.2 Abdominal migraine
1.6.2 Benign paroxysmal vertigo
1.6.3 Benign paroxysmal torticollis





information around the root cause and complexities regarding its pathogenesis. The next 
section will highlight various treatment options currently available to manage migraine. 
 
 Treatment 
The treatment options for migraine can be either a preventative approach or an abortive 
approach (Fig.1.5). There may be several co-existing conditions at the time of diagnosis, 
such as with secondary headaches (see section.1.2.1.). Educating the patient about the 
common migraine triggers such as dietary triggers, hormonal changes, irregular sleep 
patterns, sensitivity to climatic temperature and weather patterns, emotional stress and 
irregular meal habits is very important in helping them to manage migraine by introducing 
some life style changes (7, 39). Once the triggers are identified with the help of their 
medical practitioner, changes in their lifestyles can bring some improvements in the 
frequency of incidence. Along with life style changes, Non-Steroid Anti-Inflammatory Drugs 
(NSAIDs), β-blockers, anti-depressants, combination analgesics, dopamine antagonists, 
corticosteroids, opioids, triptans etc. are medications (Fig.1.5, 1.6 & 1.7) commonly 
prescribed in migraine. Acute treatment of migraine is most suitable during the prodromal 
phase i.e., the early headache phase. Use of migraine specific medications were shown to 
be better, compared to non-specific therapies as demonstrated in figure 1.5. Oral NSAIDs 
and acetaminophen in combination with caffeine are known to relieve symptoms. Gastric 
side effects may be the main limiting factor with most of the combination therapies. 
Careful patient monitoring is required to avoid drug dependency leading to drug overuse 
symptoms such as, drug overuse headaches, and potential for withdrawal symptoms. 10–
20% of the refractory headache patients (who did not respond to common analgesics) 
subsequently selected for chronic opioid therapy (such as codeine), responded with 





     






Figure 1.5 Migraine treatment goals and anti-migraine treatment options currently in practise. 








































Figure 1.6 List of anti-migraine drugs and their chemical structures. 
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Figure 1.7 List of anti-migraine drugs continued. 





Both ergotamine and DHE are known to be migraine specific medications, the same is true 
with triptans. The first triptan injectable medication: sumatriptan was developed in 1992 
as a migraine specific medication. These drugs are known to relieve symptoms due to their 
vasoconstrictive and neurogenic anti- inflammatory properties (39). Acute anti-migraine 
effects of triptans are assumed to be attributed due to their agonistic serotonergic 
properties (40). Over the past 20 years more triptans have been approved by the US FDA 
are: eletriptan, almotriptan, frovatriptan, zolmitriptan, naratriptan, and rizatriptan. There 
are some concerns regarding their cardiovascular side effects and drug interactions when 
co prescribed with other medications. Most of the triptans are available as oral tablets, 
while a few are also available as nasal sprays like, sumatriptan and zolmitriptan. Certain 
neuroleptics like metoclopramide are found to be effective when co-prescribed to relieve 
symptoms of nausea (7). Figure 1.5 represents a sample migraine treatment model, 
currently practised globally, drafted based on the above information. 
 
 Current treatment success with anti-migraine treatment  
 
A published meta-analysis study of anti-migraine treatment results from 24,089 patients in 
53 controlled clinical trials of triptans demonstrated that triptans were an effective 
treatment of choice, and that some triptans were better choice over others in terms of  
sustained freedom from pain (40). These response rates were higher with higher doses of 
drugs such as rizatriptan 10 mg, eletriptan 80 mg, and almotriptan 12.5 mg than with their 
respective lower doses and all the responses were compared with sumatriptan 100 mg as 














Figure 1.8 A meta-analysis data of treatment responses to anti-migraine drugs (Images reproduced from the 
New England journal of medicine 2002, by Goadsbey et al. with copyright permission to reproduce in 
academic works). The boxed region represents response of reference drug - sumatriptan 100 mg at 95% 
confidence interval (40). 
Since lower doses of eletriptan had poor results it could be assumed that at higher doses, 
both drug availability and drug distribution might have improved the drug response. For 
improved drug response, the drug needs to cross the BBB and activate 5-HTRs in the brain. 
As we notice there is a significant response at 80 mg v/s 20 mg of eletriptan. Could this be 
contributed due to the drug being able to activate a few more of the 5-HTR’s in the brain? 
As it has been reported with other anti-migraine drugs like Aspirin and Sumatriptan, traces 
of the drugs were detectable in the CNS fluid following oral administration (40, 41).  
 
A meta-analysis report derived from 88 different multinational randomised double blinded 
clinical trials conducted and published between 1993 and 2016, had clinical outcome 
analysis of NSAIDs and triptans as the most preferred treatment option in migraine, with a 
total of 34, 850 participants (42). The authors of this meta-analysis concluded that, 





eletriptan may be the most suitable therapy for migraine and ibuprofen might be a good 
alternative as its tolerability was better with patients (42). Sumatriptan 100 mg and 50 mg, 
provided good efficacy and tolerability and by far the longest clinical experience recorded 
since its introduction. The 6 mg subcutaneous formulation of sumatriptan is the most 
effective for acute migraine treatment, however it is also associated with more intense 
adverse events (AEs) and the need for self-injection to avoid daily clinic visits. Naratriptan 
2.5 mg offers very good tolerability and can be useful in patients with mild or moderate 
migraine. Zolmitriptan was a good treatment alternative in many patients with migraine 
symptoms; however, this may not offer any specific advantage over other triptans. 
Frovatriptan cannot be fully judged in view of the lack of data but does not seem to offer 
any advantage over sumatriptan either (40, 43). 
The results of the meta-analysis study from 53 clinical trials (12 unpublished) involving 
patients with oral triptan medication, have shown that rizatriptan (10mg), almotriptan, and 
eletriptan (80mg) have a better response compared to sumatriptan in terms of headache 
response at 2 hrs and total pain-free responses (44). All triptans in general have better 
responses than placebo, however there have been concerns regarding their potential for 
cardiovascular side effects like coronary vasoconstriction, hence precautions were required 
for patients with cardiovascular complications. Sumatriptan is the first and most widely 
prescribed triptan, in most of the European countries and North America (44).  Data from 
the above meta-analysis suggests that mean absolute response with sumatriptan 100 mg 
for headache response were approximately 60% and zolmitriptan, rizatriptan eletriptan 80 
mg and almotriptan were better treatment choices. However, mean absolute pain free 
responses for sumatriptan 100 mg were only less than 30% and zolmitriptan 5 mg, 
rizatriptan 10 mg, almotriptan and eletriptan 80 mg showed higher response than 
sumatriptan 100 mg. What is noticeable among the treatment responses is the increase of 
responses with higher doses of some drugs especially eletriptan 80 mg over, 20 mg is of 
high interest as we could assume that at higher doses, more traces of the drugs are able to 
cross the BBB and detectable in central nervous system (CNS) fluids. This is also true with 
other anti-migraine drugs as aspirin and sumatriptan have shown traces of the drug 
available in CNS fluid after administering the 





drug orally (41). The mode of action (MOA) of anti-migraine drugs, specifically triptans, is 
believed to involve 5-HTR’s (44), which suggest exploring the role of neurotransmitters 
such as 5-HT in migraine would add to a better understanding of this disorder. 
1.3 The role of neurotransmitters in migraine 
 
The role of neurotransmitters (DA & 5-HT) in migraine and its significance in triggering 
migraine, would be an interesting topic to research, more so due to their structural analogy 
to dietary amino acids, and their role in neurobiological symptoms such as hypersensitivity 
to sensory stimuli.  Otto Loewi discovered the first neurotransmitter in 1926, during a lab 
demonstration, wherein he noticed acetylcholine acted as a chemical messenger via the 
vagus nerve to the heart in lowering the cardiac rhythm by activating certain receptors. 
Since then, several biochemicals and their respective receptors have been researched in 
synaptic transmission (45).  
 Neurotransmitters in synapses  
Neurotransmitters play a crucial role in facilitating the communication channels within the 
CNS via its (neurotransmitter’s) release into synapses. Communications within the brain 
and between brain & the rest of the body are facilitated via this neurotransmission 
involving synapses (Fig.1.9); which are the contact junctions between adjacent neurons. 
Neurotransmitters could be made up of mono amines, AAs or peptides. Examples of 
monoamine neurotransmitters are 5-HT, DA, NE, epinephrine, histamine, etc., and some 
AA that act as neurotransmitters are glycine, aspartate, glutamate, etc. Somatostatin and 
substance P are peptide neurotransmitters (Fig 1.10). Neurotransmitters are usually 
biosynthesised from their precursor amino acids, e.g., 5-HT biosynthesised from 
tryptophan (Fig. 1.11). There are a vast number of ‘biochemicals’ endogenously 
synthesised in neurons and stored within neuronal vesicles, which then act as 
neurotransmitters upon release into the gaps between neurons at the synapse called the 
synaptic cleft (or synaptic gaps); except gaseous neurotransmitters such as CO and NO, 
which are not stored in neuronal vesicles. Upon stimulation by an incoming AP or nerve 
impulse to the neuron, Ca2+ channels on the cell membrane open to allow Ca2+ entry into 
the neuron, which in turn activates neuronal vesicles to move towards the synaptic cleft to 
allow neurotransmitter release. Upon release into the synaptic cleft, the neurotransmitters 





bind to specific receptors on target neurons or may get metabolised by enzymes present in 
the synaptic cleft or recycled back to pre-synaptic neurons via transporter proteins 
 
Figure 1.9 A schematic representation of an enlarged inter-neuronal junction called synapse, where 
transmission of neurotransmitters mediate communication network within central nervous system. An 
incoming action potential (AP) initiates the Ca2+ entry to neuron, which then stimulates neuronal vesicle to 
move towards the synaptic cleft and diffuse with the cell membrane to release the neurotransmitters into the 
synaptic cleft.  
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Figure 1.10 Examples of neurotransmitters (substance P & 5-HT) and their respective receptors. 
 
embedded on the cell membrane of presynaptic neurons (Fig. 1.10). Post synaptic neurons 
upon receiving the neurotransmitter-receptor binding, activate these receptors to initiate 
further changes in the postsynaptic neurons and propagates the action potential (AP) 
down the line. This activation of receptors and conduction of AP goes on until the CNS 
communication reaches the destination, and the subsequent desirable changes happen 
further down the process. During this process of neurotransmission, the signals can be 
modified (the signal intensity can be enhanced or reduced) or stopped by other intervening 
receptor proteins, such as gamma-aminobutyric acid (GABA) receptors and glutamate 
receptors from neurons at synapses (Fig. 1.20). 5-HT is one such neurotransmitter which is 
released in many serotonergic neuronal synapses as part of the communication channel 
between the brain and other body parts (e.g., smooth muscles on blood vessels) and are 
biosynthesised and stored in neuronal vesicles. 





 5-HT biosynthesis and degradation 
Serotonin is biosynthesized, from the amino acid tryptophan (Fig.1.11), which undergoes 
hydroxylation via tryptophan hydroxylase (TH) enzyme to give rise to 5-hydroxy tryptophan 
(5-HTP) which is then decarboxylated to serotonin in the presence of enzyme, aromatic 
amino acid decarboxylase, then later metabolized to 5-hydroxy indole acetic acid (5-HIAA), 
via enzymes MAO and AD (aldehyde dehydrogenase) (46). 5-HT can also alternately 
metabolise to a different product as melatonin in brain which aids in sleep (47). 
Serotonergic neurons store the biosynthesised 5-HT in their neuronal vesicles, upon 
stimulation by AP signals, 5-HT is released into the synaptic cleft, as described in section 
1.3.1 (Fig. 1.9). Excess 5-HT from the synaptic cleft is recycled back to neuronal vesicles via 
transporter proteins on the presynaptic neuron and the non-recycled 5-HT, is then 
degraded (Fig. 1.11) and removed from the system. Similarly, dopaminergic neurons have 
DA stored in place of 5-HT in their neuronal vesicles as described above is released into the 
synapses upon activation by AP. Neurotransmission processes involving 5-HT & DA are 
important because they play a crucial role in maintaining a good overall mental health 
(reduces anxiety), maintaining alertness, relaxation, and calming effects (48). DA is known 
to have effects on cognitive function and mental sharpness while 5-HT on relaxation, and 
calming effects (49, 50). 5-HT/ DA are synthesized in presynaptic neuron and stored in 
vesicles as mentioned earlier, on stimulation they are released into synapses, where they 
must bind to their post synaptic neuroreceptors to initiate various signalling mechanism to 
relay their effect. Excess 5-HT/ DA are either degraded via enzymes or recycled back to pre-
synaptic nerve via their transporters. The serotonin receptors are activated by the 
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Figure 1.11 Biosynthesis of Serotonin  and degradation to 5-HIAA; alternately 5-HT can be metabolised to 
melatonin as well which aids in sleep. 
MAO (Monoamine oxidase), AD (Aldehyde dehydrogenase). 
 
5-HT does not cross the blood brain barrier and hence dietary supplements are not likely to 
have any effect on altering their availability in brain, however dietary tryptophan is linked 
to elevated availability in brain (51), as they are a precursor to 5-HT.  The same is also true 
with DA, as it cannot cross the BBB. AAs such as phenylalanine and tyrosine act as 
precursors to DA biosynthesis and DA itself is known to be precursor to NE. Thus 5-HT, DA 
& NE are important neurotransmitters, which aid communication between the brain and 





the rest of the body as well as a regulatory role between them by influencing each other’s 
level in the system. 
In several migraine studies plasma levels of 5-HIAA and 5-HT are studied (48), to 
understand their role implicated at various stages of migraine.  When 5-HT is released into 
the synapse, they bind to specific receptors on post synaptic neurons, to initiate signalling 
processes depending on the receptor subtypes they activate. The same is true with DA and 
NE. 
 
  5-HT & DA receptors and their subtypes 
5-HT receptors known as 5-hydroxytryptamine receptors (5-HTRs) are localised mainly in 
the gastrointestinal tract (in enterochromaffin cells) (52) and in brain nuclei (raphe 
nucleus) more frequently (53). 5-HTRs are a group of G protein-coupled receptors (GPCRs) 
and ligand-gated ion channels (LGICs) found in the central and peripheral nervous systems 
(54, 55). These receptors initiate signalling mechanism upon activation by the specific 
neurotransmitters as their natural ligands and depending on the receptor subtype, they 
could initiate an appropriate signalling mechanism, and pass on the AP, which is most likely 
due to depolarisation of the post synaptic nerve, where the permeability to certain ions 
changes due to the signalling process initiated by ligands via the receptors, which is still not 
fully understood and is an extensively researched topic (56). 5-HTR signalling down the 
line, can modulate the release of many neurotransmitters, including DA. Thus 5-HTRs are 
activated by their natural ligand 5-HT, which is also a neurotransmitter. and the same is 
true with DA receptors and DA. DA- or 5-HT-mediated synapses exist between nerves and 
blood vessel walls, resulting in agonistic or antagonistic activation of their respective 
receptors depending on the receptor subtypes it activates, as some receptor subtypes are 
inhibitory in nature and some are excitatory in nature (54, 56-59). Both DA and 5-HT 
receptor subtypes are extensively researched by scientists today and more research is still 
needed to fully understand their signalling mechanisms. The intensity of neurotransmitter 
signals from the synapses could be modified further, as mentioned earlier, by certain 
signalling proteins embedded in the nerve cell membrane such as glutamatergic or 
GABAergic post synaptic nerves in synapses as mentioned earlier in section 1.3.1.  
 





DA/5-HT receptors are known to have several subtypes, and are located throughout the 
brain, spinal cord, blood vessels and peripheral nerves. DA/5-HT receptors in the brain, are 
implicated in intracranial vasoconstriction. On the other hand, intracranial vasodilatation is 
thought to be involved in the activation of the trigemino-vascular system which stimulates 
the release of vasoactive sensory neuropeptides, especially calcitonin gene-related peptide 
(CGRP) from trigeminal ganglia cells, which increases the pain response, and can be an 
important pathogenesis process during migraine (48). An agonistic activation, of 5-HT 
receptors in intracranial blood vessels, is indirectly involved in stopping the stimulation of 
this above pathogenesis process and production of CGRP (48).  
Sokolov et al. (2011) (48) suggested there are at least 15 units of known serotonin 
receptors, of which only a few could be implicated in the pathogenesis of primary 
headaches and, particularly in the case of migraine headaches; such as 4 units of 5-HT1 
type, e.g. 5HT1A, 5-HT1B, 5-HT1D, 5-HT1F, and 3 units of 5-HT2 type, e.g. 5-HT2A, 5-HT2B, 5-
HT 2C. There are two families of DA receptors, called D1 and D2; the D1 family consists of D1 
& D5 receptor subtypes and the D2 family consists of D2, D3, and D4 receptor subtypes. 
However, according to Stephen et al. (1997) (43), activation of the D2 receptor is thought 
to contribute to the pathogenesis of migraine, and as a result D2 antagonists might 
effectively manage the disorder. Hence it would be interesting to explore molecular mimics 
of neurotransmitters and the possibility of them activating these receptors, which could be 
implicated in the pathogenesis of migraine, such as tyramine. Drugs can be designed to 
target these receptors to bring desirable activation of these receptors, or stop the 
pathogenic signalling of the receptors, provided we understand the pathogenesis of the 
disorder and the cellular signalling mechanisms implicated in the pathogenesis process of 
migraine.  
 Can anti-migraine drugs act at 5-HT/DA receptors? 
 
 Hargreaves et al. (1999) (14) suggested that all triptans act as serotonergic agonists by 
binding to 5- HT1B receptors expressed in human intracranial arteries, causing 
vasoconstriction and by inhibiting nociceptive transmission through an action at 5-HT1D 
receptors expressed in the meninges and in brain stem nuclei (14). Thus, the antimigraine 
agents which are 5-HT1B or 5-HT1D agonists are effective against migraine headache pain as 





they reverse the intracranial vasodilation, implicated in the pathogenesis of migraine and 
its associated symptoms. This might explain the link between migraine headaches 
(production of CGRP), and localized brain blood pressure changes as observed during CSD 
involving vasodilation/vasoconstriction associated with hyperaemia/oligaemia, which  
might have links to DA/5-HT irregularities (48). Section 1.2.2 described the current 
treatment modalities, in which a cocktail of drugs from anti-hypertensives to 
anticonvulsants being used to treat migraine. However, the MOA of these drugs suggests 
that it is the symptoms that are getting managed and not the disorder itself.  
 Is there any rationale behind the usage of β-blockers, anticonvulsants, NSAIDs and 
Vitamin-B’s in migraine treatment? 
 
As there are a wide range of triggers known to cause migraine, so are also the many 
treatment options available today. As mentioned before from the use of certain β-blockers, 
anticonvulsants, NSAIDs to vitamin B are all known to be useful in the management of 
migraine disorder (26, 60). This cocktail of different kinds of medication itself is an 
indication that there is no definitive approach for managing migraine, and that it is treated 
symptomatically; hence there is this complex mix of treatment pattern being practised. If 
all these diverse types of drugs are giving relief in the migraine patient, then there could be 
a common aspect of this mix of drugs contributing to the treatment success. In this context 
it will be interesting to explore this common factor that leads to treatment response amid 
such a complex mix of cocktail drug approach. Could it be the serotonin structural analogy? 
If such a structural analogy exists among anti-migraine drugs to a common molecule such 
as  5-HT or DA, and if we can establish this concept then we could explore the significance 
of this structural analogy in linking the resolution of the symptoms of migraine. 
 How does migraine link to 5-HT and DA systemic levels? 
 
Even today there is no definitive answer to the question of what underlies migraine 
disorder or the phenomenon that triggers migraine headaches which is distinct from other 
headaches. Current scientific thinking points to migraine being a brain disorder linking 
either partly or fully to 5-HT and/or DA and their receptors, involving multiple triggering 
mechanisms leading to the disorder (26, 40, 55). Both DA and 5-HT have important roles in 





the brain, such as the one mentioned before with 5-HT having cognitive functions in the 
brain, including memory and learning. Dysfunctions of the dopaminergic system, relating 
to the loss of dopamine-secreting neurons in the midbrain area, called the substantia nigra 
is associated with several important diseases of the nervous system including Parkinson's 
disease. Similarly, serotonergic systems are targeted by antidepressant agents to modulate 
5-HT at the synapses. Hence, if DA and 5-HT are implicated in migraine, this would further 
add to the complexity of their role (26, 33) . The concentrations of 5-HT and DA in the 
synapse are important in determining their neurotransmission effects. There are several 
synaptic concentration control mechanisms involved to check its concentration in the 
synapse with the help of several presynaptic receptors and transporters (Fig. 1.9). This 
control mechanism ensures a fine balance of synaptic neurotransmitter concentrations. 
Whether interactions involving post-synaptic receptors, or pre-synaptic inhibitory 
receptors and/or transporters are implicated in the manifestation of the disorder is a very 
complex phenomenon and needs further exploration through research. A study by 
D’Andrea et al. (2014) on the possible role of tryptophan (TRP) metabolism in chronic 
migraine (CM) and chronic tension-type headache (CTTH) found that plasma levels of 
tryptamine (TRY) were significantly lower in CM (p < 0.001) with respect to the control (61). 
TRP is a common AA precursor to both 5-HT & TRY, the same way tyrosine is a common AA 
precursor to tyramine and DA. Also, it is interesting to note that TRY can mimic 5-HT, as it 
can activate 5-HTRs (62), and the same can be hypothesised about tyramine mimicking DA 
at DA receptors. Tyramine and TRY are both biogenic amines formed from their AA 
precursors tyrosine and tryptophan respectively. In the above study, 5-HT was 
undetectable in the plasma of almost all 73 samples (from 73 patients enrolled) tested 
(61). Their results support the hypothesis that TRP metabolism is altered in CM patients, 
leading to a reduction in plasma level of TRY. Also, interestingly TRY is known to modulate 
the functions of the pain matrix (a part of CNS active during pain sensation and is 
demonstrated with an imaging technique) involving the serotonergic system. This may 
affect modulation of incoming nociceptive inputs from the trigeminal endings and 
posterior horns of the spinal cord and suggest that these biochemical abnormalities play a 
role in the pathogenicity of CM (63).  





Another study on dopamine hypersensitivity in migraine published in neurology 1997 (43), 
found that 35 migraineurs tested all had symptoms due to postsynaptic dopamine 
receptors activation (i.e., nausea and vomiting) and a lower threshold for DA receptor 
activation. In another study, Danish researchers used MRI (magnetic resonance imaging) 
scans of 19 women with migraine without aura and confirmed a significant (p=0·001) 
intracranial vasodilation observed during migraine attacks, compared to extra- cranial 
vasodilation. This indicates that future treatments need to focus on the peripheral and 
central pain pathways rather than simple vasodilation (14). It is also noticed that, 5-HT 
deficiency may result in chronic pain, sleep disturbances, anxiety, depression and a 
propensity to overeat (46). Low 5-HT levels are found in migraineurs and they suffer with 
increased frequency of depression, irritable bowel syndrome, as well as other chronic pain 
syndromes (46). Serotonin is important in the maintenance of extra cranial 
vasoconstriction and its changes in the levels in a person’s brain are found to alter their 
mood as well (46). Also, it is noteworthy that several people are treated with 
antidepressants to help with migraine relief. Hence the role of 5-HT in the pain pathway is 
an interesting topic for research, as it seems 5-HT has a role in inhibiting nociceptive 
signals. 
 
In the body, approximately 90% of 5-HT is found in stomach, and 10% in blood platelets 
(46), indicating both localised role and a hormonal messenger role. Hormonal headache 
might also have a relationship to 5-HT, since the levels of 5-HT appear to be linked to 
oestrogen levels (46). Migraine headache, as mentioned before, is thought to be 
associated with dilatation of cranial blood vessels, particularly those in the dura mater, and 
an accompanying localized sterile inflammatory response initiates the nociceptive signals 
to the brain. Both DA and 5-HT are known to play a role, via their respective receptors, in 
modulating the smooth muscle movements, such as contraction and relaxation of blood 
vessels, resulting in vasodilation and vasoconstriction via the receptor mediated cellular 
signalling mechanisms. Sumatriptan is a highly selective 5-HT1 receptor agonist which 
selectively constricts cranial blood vessels (64). Feniuk et al. (1992) also described the 
association of migraine headache with dilatation of cranial blood vessels in the dura mater, 
and sumatriptan by acting as a 5- HT1 receptor agonist, selectively constricts cranial blood 





vessels and its high efficacy in migraine supports the fact that dilatation of intracranial 
blood vessels causes pain in migraine attacks and vasoconstriction can relieve the pain 
(13). A study by Ferrari et al. (1989) reported that migraineurs had plasma 5-HT levels 
substantially higher during attack periods and the 5-HT metabolite: 5-HIAA levels, lower 
during attacks compared to healthy controls (63). Thus, it can be hypothesized that 
systemic 5-HT metabolism is enhanced in migraineurs during non-attack periods and 
substantially decreased during attacks, due to lower enzymatic degradation (63).  
 
1.3.6.1 Triptans in the treatment of migraine 
Triptans are (tryptamine based) commonly used anti-migraine drugs, known by their 
generic names such as, sumatriptan, naratriptan, rizatriptan, eletriptan, avitriptan, 
zolmitriptan, almotriptan , frovatriptan, and donitriptan. It is interesting to note that 
Tryptamines are structurally analogous to tryptophan, an essential dietary amino acid (Fig: 
1.12) from which 5-HT is biosynthesized. It is well known that amino acids, which are 
structurally related, can have similar functional properties. Hence triptans which are 
structurally related to 5-HT, may act like 5-HT at their receptors, especially in the absence 
of 5-HT thus correcting the systemic imbalance, and providing symptomatic relief when 
used as anti-migraine drugs. However, for this effect to happen they may need to cross the 
BBB, which means the response will be poor if adequate drug concentration is not reached 
at the CNS fluid. However, there is also a wide range of non-triptan based anti-migraine 
drugs being used, as symptomatic treatment options, including beta blockers, calcium 
channel antagonists, antidepressants, nonsteroidal anti-inflammatory drugs (NSAIDs), 
anticonvulsants and vitamin B’s. Though the anti-migraine drugs are effective in treatment, 
their exact mode of action in relieving the disorder is still not clearly understood. 
Pharmaceutical medicines article (2015) (26) by authors Brinsden and Shaw are having 
similar work on anti-migraine drugs, where they have reported structural similarity 










                                                   
Tryptamine             Tryptophan         5-Hydroxytryptamine (5-HT)          Sumatriptan 
      
Figure 1.12 Above structural overlay of 5-HT (in blue) over (the other molecules in red) tryptamine, 
tryptophan, and sumatriptan, depicting structural analogy of neurotransmitter 5-HT to anti-migraine drug 
sumatriptan. Hence, we can assume that systemic availability of tryptamine and tryptophan indicate 
increased availability of systemic 5-HT as they can act as precursors and structural analogy of anti-migraine 
drugs to 5-HT indicate the possibility of mimicking 5-HT by lookalike molecules in the biological systems, 
however whether they can cross the BBB adequately is still not clear.  
 
TRY is found in trace amounts (not significant enough to be detected) in mammalian brain, 
has structural analogy to TRP and 5-HT, when compared to their molecular structures 
(Figure 1.12), and they are all structurally analogous to antimigraine drugs such as triptans, 
e.g., sumatriptan. Triptans are well known tryptamine based anti-migraine drugs, and that 
when we study their molecular structures, all triptans share this common tryptamine 
molecular structure in them, hence this also suggests that there is a high possibility of 
mimicking 5-HT (as discussed previously) by the triptans, due to this commonality of their 
structure. Hence it cannot be a coincidence that all anti-migraine drugs which are effective 
in treating migraine, share a structurally common molecule such as 5-HT, as they are found 
to be activating 5-HT receptors which could be a contributing factor to their drug efficacy. 
As discussed earlier, 5-HT aids in the vasoconstriction of intracranial arterial blood vessels, 
which provides relief to migraine symptoms and DA could most likely be involved in the 
vasodilation, which needs further investigation. From the above discussions it can be 
logically concluded that 5-HT and DA has a role in the development & management of 
migraine, as we could assume lack of activation of serotonergic system is not able to 
reverse the vasodilation of intracranial arterial blood vessels, which is causing 
inflammatory response and pain symptoms in migraine. Hence both dopaminergic and 
serotonergic system needs further research in understanding their contribution to this 





vasodilation (by DA/NE), subsequent pathogenic response leading to migraine and the role 
of 5-HT in vasoconstriction. 
 
1.4 Understanding the pathogenesis and nociception in migraine  
 
Current understanding of migraine suggests that, the primary dysfunction begins within 
the CNS, which then leads to changes in the contractility of blood vessel walls causing 
vasodilation of the intracranial meningeal structures, stimulating a sterile inflammatory 
response and subsequent symptoms of migraine. Do the current anti-migraine drugs good 
enough to penetrate the CNS and target this primary disfunction? Not necessarily and that 
explains the low drug efficacy in migraine treatment. It is believed that genetically 
predisposing factors could be implicated in the pathogenesis of this neurovascular 
disorder, with abnormalities at the cellular levels, responsible for lowering the threshold to 
migraine specific trigger factors, in the brain of a migraineur compared to a normal 
individual. However, the exact nature of the CNS dysfunction leading to CSD like 
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Based on the current scientific understandings, a key mechanism underlying the 
generation of headache pain associated with migraine are, the vasodilatation of 
intracranial & extracerebral blood vessels and a subsequent stimulation of trigeminal 
sensory nervous pain pathways involving the brain stem nuclei. 
The network of trigeminal nerves and the associated intracranial blood vessels collectively 
known as trigemino-vascular system; its activation is thought to be responsible for the 
release of vasoactive sensory neuropeptides, such as CGRP, substance P etc. which in turn 
activates the brainstem nuclei causing increase in the pain response during a migraine 
attack (figure 1.13). The activated brainstem trigeminal sensory nuclei relay the pain 
signals to higher centres in brain where headache pain is perceived (14). 
 
 How anti-migraine agents resolve pain in migraine? 
 
The anti-migraine agents such as triptans can act as serotonergic agonists at 5-HT1B 
receptors expressed in human intracranial arteries, resulting in vasoconstriction and 
inhibition of nociceptive transmission through an action at 5-HT1D receptors on peripheral 
nerve terminals in the meninges and central terminals in brain stem sensory nuclei (14). 
These three complementary sites of action i.e., 5-HT1B receptors on the intracranial 
arteries, together with 5-HT1D receptors on meningeal nerves and in brain stem nuclei 
(Fig.1.16) underlie the clinical effectiveness of triptans against migraine headache pain and 
its associated symptoms (14). 
 Brain stem nuclei as pain modulation centres 
Meninges in the extracerebral region have serotonergic neurons, innervating the 
meningeal blood vessels, which act as afferents to pass impulses via the trigeminal and 
pterygopalatine ganglions from the brain nuclei as in Figure 1.15. This network may be 
communicating the afferent nociceptive information to the brain nuclei, where the 
nociceptive impulses are further modified before passing on to the higher centres in the 
brain. In the brain stem nuclei, such as raphe nuclei and locus ceruleus are known to have 
high concentrations of 5-HT and DA respectively, indicate their potential role in modulating 
nociceptive impulses. 





 Monoaminergic system in brain nuclei 
Migraine might involve dysfunctions in the modulation of sensory inputs in the brain-stem 
pathways. And we may assume that monoamines such as, 5-HT, DA & NE have a role in 
modulating theses inputs via the raphe nuclei and the locus ceruleus (Fig.1.15 & 1.18).  
The trigeminovascular input from the afferent nerves innervating meningeal blood vessels 
pass through several nerve structures like, the trigeminal ganglion, second order neurons 
in the trigeminocervical complex, the quintothalamic tract, and then branch out in the 
brain stem, and synapses with neurons in the thalamus (40). There are several nerve 
connections between neurons in the pons in the superior salivatory nucleus, 
parasympathetic ganglia innervated by nerves from facial region. This trigeminal ganglion 
network may be expressed more strongly in patients with cluster headache and may be 
highly active in migraine, this may explain the aura symptoms associated with migraine as 
explained in section 1.1.2, such as sensory aura, aphasic aura, motor aura etc. 
 .  
 
 Figure 1.14 Possible pathways of nociceptive impulses in migraine. 
Possible transmission of nociceptive impulses, their modulation, and processing pathway in migraine. Certain 
proteins at neuro junctions can control local concentrations of monoamines are DAT-Dopamine Transporter; 
NET- Norepinephrine Transporter; SERT - Serotonin Reuptake Transporter, some neurotransmitters that can 
accentuate or inhibit the impulses activated by monoamines are glutamate, GABA etc., neuropeptides that 
can activate nociception in brain stem are e.g. substance P and CGRP, certain chemicals that can reduce or 
increase inflammation such as enkephalins, NO etc. 
 





Brain imaging studies suggest that important modulations of the trigemino-vascular 
nociceptive inputs come from the dorsal raphe nucleus (which has high presence of 5-
HTR), locus ceruleus (has high DA concentrations), and nucleus raphe magnus (Fig.1.15) 
(40). The migraine pain pathway (Figure 1.14) encompasses the nociceptive afferents from 
the meningeal blood vessels, neurons of the dorsal horn, surrounding neurons of dorsal 
root ganglion and a distributed supraspinal network that modulates relay and processing of 
nociceptive inputs to the dorsal horn.  
 
Figure 1.15- Trigemino-vascular network components in brain stem (Images borrowed from Goadsby et al. 
article from New England Journal of medicine 2002 (40) with copy right permissions to reproduce in 
academic work, inset brain model downloaded from MS word online pictures which doesn’t need copy rights 
permissions). Additional brain model in the inset, displays regions highlighted with blue stars to depict the 
likely distribution of 5-HTRs. Extracerebral regions including meninges are densely innervated by 
neurovascular network which act as afferents in transmitting nociceptive impulses upon non-sterile 
inflammation due to increased blood flow during a migraine attack. Brainstem in the intracranial region has 
both serotonergic as well as dopaminergic neurons via dorsal raphe nuclei and locus ceruleus. Trigeminal 
ganglion mediates connections between extracerebral, intra-cranial neuron pathways to the trigeminal 
nuclei, especially when all the important brain nuclei are centred in the brain stem. 
 





The glutamatergic inputs as illustrated in Figure 1.14 can enhance the nociceptive signals 
from sensory afferents to several laminae of the spinal dorsal horn. Neuropeptides, such as 
substance P and CGRP can be released by sensory afferents in brain (including meninges) 
and thus this in turn can sensitise dorsal horn neurons resulting in neuropathic pain such as 
migraine (Fig.1.14) (15). 
 
As per Benarroch et al. (2008) nerve impulses from spinal cord areas such as Lamina I and 
lamina V, comprising the spinothalamic tract which conveys nociceptive inputs to the 
hypothalamus, amygdala, periaqueductal gray (PAG), and rostral ventromedial medulla 
(RVMM) (15). Lamina II contains inhibitory GABAergic interneurons that utilize glycine, or 
opioids such as enkephalins, and provide impulses to communicate or inhibition of 
nociceptive signals to the spinothalamic and spinobulbar projection neurons. 5-HT, DA and 
NE play a vital role in transmitting nociceptive impulses by being pro-nociceptive or anti-
nociceptive at their selective receptor sub types (Fig.1.18). By being either anti-nociceptive 
or pro-nociceptive at their selective receptor subtypes, these neurotransmitters can 
modulate or control nociceptive impulses, which is crucial in activating pain sensations as 
illustrated in Figure 1.16. Once the pain is activated, the intensity can be accentuated by 
other intervening glutamatergic nerves or ameliorated by GABAergic inhibitory neurons as 
illustrated in Figure 1.20. This kind of emphasising bidirectional influences on pain 
sensation can either inhibit or facilitate transmission of nociceptive impulses at the dorsal 
horn area of brain. These modulatory effects are largely mediated by descending 
monoaminergic pathways that utilize serotonin, norepinephrine, or dopamine as 
illustrated in Figure 1.18.  
 
The descending monoaminergic system processing nociceptive impulses are in the dorsal 
horn region of brain. Processing these impulses and their effects in the dorsal horn are 
complex. Monoamines may act via different subtypes of receptors between their locations 
at peripheral afferents like meningeal nerves and dorsal horn projection neurons and may 
involve other local excitatory or inhibitory interneurons such as GABAergic and 
glutamatergic neurons, and glial cells. Serotonin, norepinephrine, and dopamine may exert 
either antinociceptive or pronociceptive effects according to the type of receptor sub type 





involved, site of action in the dorsal horn, brain nuclei or at peripheral afferents and 
crosstalk between descending monoaminergic systems including DA/NE and local 
neurochemical signals, including NO, adenosine and endogenous opioids such as 
enkephalins (Fig.1.19) (15). In addition, concentration of monoamines in the dorsal horn 
and brain stem are regulated via controlled release and reuptake mechanism at the 
synaptic clefts (15). 
 
 Deactivation of nociception in migraine by 5-HTRs 
 
5-HTRs play a crucial role in migraine (Figure 1.16), as their vasoconstrictive effect can 
correct the inflammation at meningeal blood vessels via 5-HT1B and may help reduce the 
blood flow in brain at the same time. 5-HT1D receptors inhibit nociceptive transmission via 
CGRP inhibition as described in figure 1.16, however in the absence of these receptor 
activations, migraine symptoms may start to develop, and when an anti-migraine drug is 
administered it might correct the situation by mimicking the natural ligand and activate 
these receptors and correct the situation to relieve the symptoms.   
 
Hence the underlying mechanism we may assume, that leads to the migraine disorder 
could be the 5-HT/DA dyshomeostasis, leading to hyperactivation /sensitisation of brain 
centres and that the triptans are able to partially correct this dyshomeostasis. Figure 1.16 
illustrates the neurotransmission pathway of 5-HTRs between brain nuclei and blood 
vessels via trigeminal ganglion, and the communications between higher centres in brain 
and the dorsal horn with brain nuclei in controlling the nociception pathways. 




















Figure 1.16 A schematic representation of the signalling pathway of neurotransmission resulting in 
vasoconstriction of blood vessels, due to the presumed activation of 5-HTRs by natural ligands or by anti-
migraine drugs such as triptans.  
 
 
 Other predisposing factors in migraine: the role of DA lookalike- ‘tyramine’ 
 
In a double-blind study (65) on the effect of tyramine in migraine, the 
electroencephalogram changes observed as part of the study observations supported the 
hypothesis that tyramine has an action on the central nervous system in some migraine 
patients (65). As tyramine is a biogenic amine as mentioned earlier, derived from AA 
tyrosine, available through our daily dietary intake and has a close structural analogy to 
dopamine (DA), which will be interesting to correlate their role and explore their influence 
due to this structural analogy. 
 
(by inhibiting the 
release of CGRP) 





A cross-sectional study published in The Lancet Neurology 2013 (66), has used magnetic 
resonance angiography of intracranial arteries in patients with spontaneous migraine 
without aura, suggests that migraine pain was accompanied by slight intracranial 
dilatation, this supports the understanding that migraine headache might originate from 
dilated intra cranial arteries involving neurobiological mechanisms, hence future migraine 
research focusing on the peripheral and central pain pathways involving trigeminal nervous 
system would be interesting to help further understandings on pathogenesis of migraine. 
 
 Genetic factors 
 
Though there are varying theories; the specific cause of common forms of migraine 
headache is still unknown, however, studies on families suffering from familial hemiplegic 
migraine (FHM) have suggested that genetic factors may be involved (14). The occurrence 
and frequency of attacks in any individual will be influenced by their CNS response to 
migraine specific triggers (e.g. certain foods, hormone levels in blood, changes in levels of 
stress, reading habits and even exposure to light and sound). It has been hypothesized that 
genetic abnormalities result in a lowered CNS threshold of response to these specific 
trigger factors in migraineurs, that means even a low level of trigger can activate a 
response at the brain stem, or in other words the brain stem nuclei are more sensitised to 
triggers than in a normal person. Hence, we could assume that the trigger factors can 
influence as modulators of the genetic set point that predisposes to migraine, however this 
modulatory influence is only assumed as nothing is proven as a clear factor in influencing 
the response mechanism at the brain nuclei in a migraine patient. It is possible that the 
unusual hyper-responsivity of the brain in migraineurs, like FHM, may be a consequence of 
mutations in the ion channels that regulate neuronal excitability. This has given rise to the 
description of migraine as a channelopathy wherein irregularities in the functioning of ion 
channels leading to improper firing of signals from neurons. As we know from earlier 
section 1.2.1, that to conduct an AP via synapse, ion channels like Ca2+ ion channels, must 
allow inflow of Ca2+ ions to excite neurotransmitter vesicles to move towards the synapse 
to release the neurotransmitters to the synapse. Only then the AP is transmitted to the 
post synaptic neurons, via these neurotransmitters which then binds to the respective 





receptors in the post synaptic neurons to pass on the impulses. The theory suggests that, 
due to this channelopathy, migraine specific triggers can provoke or activate CNS as 
explained in section 1.4.3 and lead to dysfunctions characterised by initiation of migraine 
specific symptoms such as experiencing sensory auras, characterised by visual 
disturbances, photophobia, hypersensitivity to sound, smell etc. In this context the 
presence of blood flow changes, such as oligaemia and hyperaemia, could be an indicative 
of altered CNS activation and have supported a role for CSD or activation of early 
symptoms of migraine (especially with aura). CNS dysfunction produced by various 
migraine trigger factors could be an explanation as to why some patients who present 
symptoms of migraine with aura and some without aura. This was supported by the 
observation that patients with no history of migraine developed migraine-like episodes 
after surgery to implant electrodes in the periaqueductal grey matter and raphe nuclei in 
the brain stem (14). 
Another hypothesis is that the primary dysfunction in migraine occurs within the CNS 
leading to changes in blood vessels within pain-producing intracranial meningeal structures 
that give rise to headache pain. Hence, migraine is now thought to be of a neurovascular 
and neurobiological disorder. It has been proposed that genetic abnormalities may be 
responsible for altering the CNS response threshold, to migraine specific trigger factors of a 
migraineur compared to a normal individual (14). Though there are varying explanations to 
the nature of the CNS dysfunction that result in migraine, it is still not clear to point to a 
single cause and also that, what could trigger the CSD like phenomena and activation of 
nociceptive mechanism in brain stem nuclei involving dorsal horn in migraine patients need 
to be further investigated (14). It is generally thought that cerebral vasodilation and a 
consequent stimulation of surrounding trigeminal sensory nervous pain pathways is a key 
mechanism, as mentioned in section 1.4.3, underlay the generation of headache symptoms 










 Role of monoamines and their receptors in migraine 
 
The initiation of pain mechanism as explained in section 1.4.3 includes in general, the 
nociceptive information from peripheral nerves (afferents), a well distributed supraspinal 
network of neurons that modulates relay and processing of nociceptive inputs from several 
laminae in the dorsal horn region and central brain nuclei. Primary nociceptive afferents 
provide excitatory glutamatergic inputs to several laminae of the spinal dorsal horn. Some 
nociceptive afferents also release neuropeptides, such as substance P and CGRP (in Brain), 
which has a key role in the mechanisms of sensitization of dorsal horn neurons in 
conditions such as neuropathic pain in brain stem and possibly activating monoaminergic 
neurons, such as ‘serotonergic’, ‘dopaminergic’ and ‘noradrenergic’ neurons (Fig.1.17) in 
migraine. Some inhibitory interneurons that uses GABA, glycine, or opioids such as 
enkephalins (Fig.1.19) can provide a cross talk inhibition of monoaminergic system to the 
spinothalamic tract (STT) neurons (15).  
 
As per Benarroch et al. nerve impulses from PAG to RVMM route comprises serotonergic 
nerves, has been classically considered the primary endogenous pain modulatory system 
and target of supraspinal opioid analgesia (15). However, the RVMM contains functionally 
heterogeneous groups of serotonergic and non-serotonergic neurons that are not only 
involved in pain modulation but also in control of autonomic nervous system and other 
homeostatic functions (15). The RVMM contains two types of cells: ‘off’ cells that are 
inhibited by noxious stimulation and excited by opioids, and ‘on’ cells that have an 
opposite pattern of response (15), i.e., the ‘off’ cells inhibit nociceptive transmission, 
whereas ‘on’ cells stimulate nociception via activation of mono aminergic pathway 
between hypothalamus and spinal cord as there are both an ascending and descending 
monoaminergic pathway comprising of 5-HT, NE and DA as mono amines. However, it is 
hypothesised that, 5-HT acting via different receptor subtypes, exerts this complex ‘on’ and 
‘off’ functions on nociceptive transmission in the dorsal horn and brain nuclei. Hence the  
modulatory effect of 5-HT is a complex process involving several types of 5-HTRs, where in 
some may be activating nociception and some inhibiting nociception, which could have a 
crucial role in conditions like migraine and is extensively studied topic. 





























A11, Locus ceruleus D2, D3 (STT neuron) D1 (STT neuron) 
Figure 1.17 List of both pronociceptive and anti-nociceptive monoaminergic receptor subtypes and their 
respective neurotransmitters (Table borrowed from article by Benarroch et al., Neurology 2008 (15)) 
In specific locations of CNS (15). A11 cells are DA specific neurons and A5 are NE specific. RVMM (rostral 
ventromedial medulla); NRM (nucleus raphe magnus); STT (spinothalamic tract). 
 
 
                                  
 





                                                                                                                                                                  
                                                                                                                                                                                                          
 
Figure 1.18-Monoaminergic modulation of pain transmission in the dorsal horn involving serotonin as 
illustrated by Benarroch et al. in the Journal of Neurology 2008. (Image borrowed from article by 
Benarroch et al., Journal of Neurology 2008). 





As per Benarroch et al. (2008), activation of 5-HT1 receptors such as, 5-HT1A, 5-HT1B, &           
5-HT1D receptors inhibit nociceptive impulses (15) in STT by inhibiting neurotransmitter 
release from primary afferents probably by stopping CGRP release into synapses (Fig.1.20), 
however, 5-HT2 & 5-HT3 receptors exert a pronociceptive effect via the monoaminergic 
system (15), probably by influencing increased neurotransmitter release from primary 
nociceptive afferents. Thus serotonergic neurons have a dual role in pain processing; they 
facilitate nociceptive transmission via specific 5-HTRs and suppress the nociceptive 
transmission via another set of 5-HTRs and prevent neurogenic inflammation (15). 
The pain matrix in the CNS, includes important areas that are active in the pain modulation 
process; such as cingulate gyrus, PAG, dorsolateral pontine tegmentum, and ventromedial 
medulla (15), exert either antinociceptive or pronociceptive effects via monoaminergic 
system comprising of 5-HT, NE, or DA as their primary neurotransmitters. Hence, we can 
assume that there is a group of neurotransmitters involved in nociception and do cross talk 
between each other to modulate their impulses. There are specialised neuro-cell lines that 
express these monoaminergic receptors in the pain matrix of the CNS, such as A11 cell 
lines express DA receptors, A5 cell lines express NE receptors, where they play a role in 
nociceptive transmission. D2 agonists may facilitate antinociception by potentiating the 
effects of endogenous opioids; however, D1 agonists facilitate nociception probably by 
antagonizing D2 or opioid  
receptors. The effects of DA on spinal nociception may depend on its local concentration, 
as low levels may activate the antinociceptive D2 type receptors, whereas high levels 
activate the pro-nociceptive D1 receptors (15). Which is interesting as high levels of DA can 
facilitate inflammation and low levels inhibit the same effect; which may have a role in the 
activation of symptoms in migraine, and this is in line with earlier section 1.1.3 on 
molecular mimics of DA from dietary AAs affecting its systemic level. Hence this supports 
our assumption that molecular mimics may have a role in triggering migraine response 
from brain as high levels of DA activate the pro-nociceptive D1 receptors.  
 
The overall balance between inhibitory and excitatory supraspinal signals mediated by 
monoamines provide the basis for total modulation of pain sensation also the same area of 
brain is involved in other roles of emotional attributes such as motivation, fear, anxiety & 





other behavioural variables and has an important role in the mechanisms of inflammatory 
and neuropathic pain (15). 
 
In the dorsal horn, monoamines such as, 5-HT, NE & DA exert an antinociceptive action 
primarily by reducing neurotransmitter release from primary afferents; these effects are 
mediated by presynaptic 5-HT1B, D2 & D3 receptors, and postsynaptic inhibition of STT 
neurons. In contrast, serotonin acting via postsynaptic 5-HT2, both pre-and postsynaptic 5-
HT3 receptors, and DA, acting via D1 receptors, may have a pronociceptive effect. NE may 
elicit antinociception indirectly via GABAergic neurons probably via activating the release 
of GABA to inhibit pronociceptive signalling. Presynaptic reuptake mechanisms via 
transporter proteins and presynaptic neurotransmission inhibitory effects via GABA ergic 
neurons regulate the local levels of monoamines and thus their effects on different targets 
in the dorsal horn is a monoaminergic level dependant controlled process based on the 













Target Neurotransmitter/ Neuropeptide 
Primary nociceptive afferents Glutamate    
                      




 CGRP (Composed of 37 AA) 
Spinothalamic neurons Glutamate (refer structure above) 
 






Excitatory interneurons Glutamate (refer structure above) 
 
Inhibitory interneurons GABA 
         
Enkephalin 











Figure 1.19- Other biochemicals that contribute to nociception in migraine with their respective target 
neuron sites (Table partially borrowed from article by Benarroch et al., Neurology 2008 (15)) 
biochemicals involved in nociceptive neurotransmission at their specific target neurons, may influence or 
activate monoamines which transmit nociceptive signals, which act via different subtypes of receptors 
located at the primary nociceptive afferents, dorsal horn projection neurons, local excitatory or inhibitory 
interneurons, and glial cells (15). (AA: Amino Acid) 







Figure 1.20 Receptor-neurotransmitter activation mechanisms at synapses in dorsal horn (Image borrowed 
from article by Benarroch et al., Neurology 2008 (15)) 
Potential targets and receptor mechanisms mediating the pain modulatory effects of monoamines in the 
dorsal horn as illustrated by Benarroch et al in the Journal of Neurology 2008. Neurons involving 5-HT can 




 The role of vasoactive biochemicals and neuropeptides in migraine 
 
Primary afferents when activated due to a stimulus, can release various neuropeptides and 
biochemicals along with neurotransmitters into the synaptic junctions depending on its site 
of origin, which then activates the postsynaptic neurons via neurotransmitters. Presence of 
neuropeptides or vasoactive biochemicals can enhance the postsynaptic signalling, which 
could be an inhibitory or an agonistic response based on the type of receptors the 





neurotransmitter activates. If it activates an inhibitory neurotransmitter receptor response, 
such as an antinociceptive receptor response, then the inhibitory response is conducted 
down the line and this response can be further enhanced by a glutamatergic neuron and 
the response can be reduced by a GABA-ergic neuron. Hence the presence of a 
neuropeptide can aggravate the transmission of signals at glutamatergic neurons, which 










Figure 1.21 Vasoactive neuropeptides and biochemicals in migraine and the possible nociceptive pathways 
Vasoactive biochemicals and neuropeptides probably influencing migraine response are: Calcitonin 
Gene-Related Peptide (CGRP), Pituitary Adenylate-Cyclase Activating Peptide (PACAP), as well as 
Nitric Oxide Synthase (NOS), Adenosine Triphosphate (ATP) and Norepinephrine (NE) Vasoactive 









These vasoactive peptides activate the trigeminal ganglion (Figure 1.21), which results in 
increased extracranial blood flow and stimulation of the Superior Sagittal Sinus (SSS), which 
leads to increased cerebral blood flow (19). As mentioned before, in humans CGRP is 
elevated during the headache phase of severe and untreated migraine and cluster 
headache. Trigeminovascular nociceptive activation can contribute to the pain that is 
experienced in migraine, and that CGRP release is a major contributor to this. Imaging 
studies conducted in migraine have indicated that areas of the brainstem are active during 
migraine and involves the hypothalamus and thalamus (19). Hence brainstem areas are at 
the heart of the pain processing pathway and are therefore likely to be at the heart of 
migraine pathophysiology. What causes the activation of the brainstem and the 
trigeminovascular pathways is still debated, and that fundamentally drives migraine 
pathophysiology (19). 
 
 Nitric oxide (NO) donors and neuropeptide vasodilators as triggers of migraine 
 
NO donors, such as nitro-glycerine (consumed as a medication) and other potent 
vasodilators including CGRP, Pituitary Adenylate-Cyclase Activating Peptide (PACAP), 
Vasoactive Intestinal Peptide (VIP), and prostaglandin I2, are all likely to cause an 
immediate headache and vasodilation of intra cranial blood vessels in patients and control 
volunteers in trials tested (19). As noted in previous sections, intra cranial vasodilation is 
known to be a key mechanism triggering migraine and headache symptoms.  
Hence all biochemical vasodilators are able to trigger migraine response in migraineurs, as 
they have the potential to activate the trigeminal nervous system (19). This is because, 
these biochemicals induce nociceptive responses from the afferent meningeal nerves, 
activate trigeminal nuclei in migraine patients. Firing of these trigeminal nuclei, induce 
inflammatory response and referred to the higher order centres, such as thalamus and 
hypothalamus and this might explain the throbbing pain and other symptoms that is 
experienced in migraine (19). 
 
 





 Neurobiological events associated with migraine symptoms 
 
Aura phase, as described in previous section 1.1.2, cortical spreading depression (CSD) and 
focal neurological symptoms characterized by visual, sensory and/or dysphasic speech 
symptoms in migraine are linking to the activation of the trigeminal vascular system. 
Human studies have demonstrated a biphasic change in cortical blood flow during aura and 
leading to an initial brief hyperaemia followed by a more prolonged oligemic spreading 
across the cortex, like the phenomenon described earlier as CSD, which is understood to be 
a wave of neuronal depolarization, induced by chemical or physical stimuli, that spreads 















1.5 Known signalling pathways of serotonin  
 Serotonin and its receptors 
5-HT which is commonly known as serotonin, or 5-hydroxytryptamine or as simply as a 
general monoamine, acts in multiple roles as a biogenic molecule such as a hormone, a 
neurotransmitter, a neuromodulator, a mitogen and possibly many more roles unexplored 
(47). Dysfunctions in serotonin system such as its receptors and Serotonin Reuptake 
Transporters (SERT) are associated with irregularities of insulin sensitivity, appetite, sleep, 
organ development, behavioural disorders such as anxiety. Degeneration of serotonergic 
neurons and loss of serotonin receptors are implicated in many neuropsychological 
conditions such as, schizophrenia, clinical depression, anxiety disorders, Alzheimer’s and 
Parkinson’s disease (47). Hence serotonergic system is increasingly targeted for drug 
development, such as Selective Serotonin Reuptake Inhibitors (SSRI’s) are one such 
example of being increasingly used in most of the neuropsychiatry disorders. SSRI’s block 
SERTs there by increases the availability of extracellular 5-HT and increases their chance for 
binding to 5-HTRs (47). Increased 5-HT transmission is associated with increased adult 
neurogenesis in animal models which aids in neurodegenerative disorders such as 
Parkinson’s, Alzheimer’s and conditions of depression. 5-HTRs are thought to have 
influence on glucose homeostasis and thereby 5-HT regulates food intake, energy 
metabolism, stress responses and blood pressure via modulation of neuroendocrine and 
the autonomic nervous system pathways (47).  
 
 Early discovery of Serotonin 
 
During late 1930s, Vittorio Erspamer described 5-HT as an enteramine which is present in 
gastric mucosa and enterochromaffin extracts and can induce smooth muscle contractions. 
Later Maurice Rapport of Irvine page’s lab isolated 5-HT and reported, it can induce blood 
vessel constriction. In the early 1950s, 5-HT was recognised as having a neurotransmitter 
property and that it was found to mimic ionotropic & chronotropic effects of acetylcholine 
antagonists in heart muscles and induced relaxation of certain type of muscles. Later it was 
suggested that 5-HT could be involved in neuronal signalling as well as in regulating other 
neurotransmitters. By early 1960s the source of 5-HT in brain was identified as small 





clusters of serotonergic neurons within the raphe area of the brain now known as brain 
nuclei (56). 
 Early discovery of 5-HTRs 
About 10 years after serotonin was discovered, its receptors were identified in a study on 
gastric tissues in guinea pig, then in late 1970s, Peroutka and Snyder identified 5-HT in rat 
brain cortex tissues and were designated as 5-HT1R and 5-HT2R (56). Later Cerrito and 
Raiteri provided the first evidence of 5-HTR localisation in presynaptic neurons, which 
suggested the complexity of serotonergic system (67). Then by early 1990s to 2008, all 
subsequent families of 5-HTRs totalling to 7 members were identified as a group of GPCRs 
(G protein coupled receptors) and to date all the 14 subtypes excluding 5-HT3R, which is a 
cation channel, are categorised as a group of GPCRs (56)  
 5-HTR signalling mechanism 
Studies with partial reduction in ‘brain 5-HT’, were found to have reduced brain growth 
and cortex formation suggesting its role in multiple physiological functions (56). Imbalance 
in 5-HT signalling pathways are implicated in various pathophysiological and 
neurodegenerative disorders such as schizophrenia, Alzheimer’s disease, anxiety and 
depression (56, 68). We presently lack a complete understanding of the downstream 
molecular signalling mechanisms involving 5-HT in CNS; however, based on various 
reported evidences and events involving various subtypes of 5-HTRs in other parts of the 
body and their downstream effector molecules in different areas of brain, I will provide an 
overview of the possible signalling and the different downstream molecular mechanisms in 
neuronal disorders. However, there will be limitations to this understanding as the 
signalling will differ according to the cell type and the response from cell to other cell types 
such as the cells in gastric region and brain. 
 Considering 5-HTRs potential, in influencing wide-range of physiological functions 
throughout the body, they have become the prominent targets for pharmacological 
therapies, such as antidepressants, antipsychotics, migraine therapies, appetite 
suppressants, and drugs for the treatment of gastrointestinal disorders. The known abused 
drugs, such as the serotonergic hallucinogens e.g., lysergic acid diethylamide (LSD), DMT 
(N, N-dimethyltryptamine) and psilocybin (figure 1.22) are all known to act directly on the 
5-HTRs in CNS. These drugs by acting as ligands, at 5-HTRs are inducing signalling pathways 





by recruiting secondary molecules specific for the ligand type indicating a functional 
selectivity possibility as each ligand differ in the extent to which they stabilise a receptor 
conformation and the selection of a signalling pathway is dependent on the receptor 
conformation changes induced by a ligand and the stability of this conformation (69). 5-
HTRs are also indirect targets of psychostimulants such as amphetamines and cocaine (69).  
5-HT activates the 5-HTRs which in turn exposes its coupled Guanine nucleotide binding 
proteins (G proteins) via conformational change, which is bound to GDP (Guanosine 
diphosphate), gets phosphorylated to GTP which switches on the protein for initiating a 
signalling pathway. The heterotrimeric G proteins have 3 components viz, Gα, Gβ & Gϒ and 
in turn each of these 3 have several subtypes, such as inhibitory Gα subunit, denoted by Gi, 
stimulatory Gα subunit denoted by Gs and so on. Gq & Go are also such examples of other 
types of Gα subunits, and it is important to note that each type can initiate a unique 
pathway. Also, the fact that there are several subtypes of 5-HTRs as discussed earlier, 
which are coupled to G proteins and each 5-HTRs have a unique mechanism of signalling 
adds to the complexity of their pathways. However, all these signalling mechanisms, in 
general can be grouped to 2 main pathways for simplicity as G protein mediated and β-
arrestin mediated pathways. 
 
An agonist ligand upon binding to a GPCR can stimulate the activation of multiple signalling 
pathways, in 2 separate ways. They are G protein-mediated pathway and β-arrestin-
mediated or G protein independent pathway. Also, it is interesting to note that, the extent 
of activation of each of the downstream pathway depends upon the ligand, as it induces a 
unique receptor conformation, with some ligands, such as 5-HT lookalike drugs, promoting 
activation of one pathway over another. This concept of an agonist selectively stabilizing a 
special receptor conformation, causing the receptor to recruit secondary signalling 
molecules preferentially over another expected pathway to which it is coupled, has been 
termed functional selectivity or biased agonism (52, 56, 57, 70, 71). Some 5-HTRs coupled 
to G protein can recruit multiple signalling molecules via either G protein mediated way or 
β-arrestin way without preferring any specific pathway. However, some 5-HTRs  
(e.g. 5-HT2B) can preferentially recruit signalling molecules such as β-arrestin over G 
protein molecules, there by masking the G protein mediated signalling, referred to as a 





property called functional selectivity (72). This functional selectivity is entirely dependent 
on the unique conformational change induced by a ligand on the receptor and the stability 
of this conformational change leads to different or additional residue exposure for 
phosphorylation (69). 
 
 5-HTR signalling via β-arrestin mediated pathway 
It is now known that psychedelic drugs such as LSD (lysergic acid diethylamide) which are 
known to show their hallucinogenic properties are found to act via 5-HTRs (54), and they 
differ in recruiting the downstream signalling molecules by selectively choosing β-arrestin 
(most probably β-arrestin 1 over β-arrestin 2) pathway V/s the natural ligand 5-HT which 
seems to recruit in a non-preferential way either G protein or β-arrestin (seems β-arrestin 
2 over β-arrestin 1) and that explains the hallucinogenic property of LSD over its natural  
                          
DMT                                                         Psilocybin                                     LSD                                                 
                                           
 
                     5-HT 
 
Figure 1.22 Examples of psychedelic drugs with known serotonergic activity. Careful study of their structures 
reveal a structural analogy to 5-HT, which might have lead to their serotonergic activity. 






ligand (69, 72). It is interesting to note that 5-HT can activate extracellular signal–regulated 
kinase (ERK), or alternately known as mitogen activated protein kinase (MAPK) mediated 
pathway via G protein recruitment. However it is now not clear either via β-arrestin 2 or   
β-arrestin 1 recruitment (both generally referred to as β-arrestin), although both seem to 
have a unique pathway and if the receptor stabilises for a longer time like in LSD via β-
arrestin 2 (69), the signalling effects stay longer, and it deactivates the signalling via G 
protein pathway, which contributes to its hallucinogenic property (72). Unlike with natural 
ligand, where β-arrestin (β-AR) recruitment quickly internalises the receptor, however in 
some cases this complex is still able to activate ERK/MAPK even during and after 
internalisation (Fig. 1.23), for some time longer than expected (71, 73).
 
Figure 1.23 Depicting 5-HTR signalling mechanism via β-arrestin pathway. (Gα: alpha subunit of G protein, 
β/ϒ: beta/gamma subunit of G protein, β-AR: β-arrestin, ERK: extracellular signal–regulated kinases, MAPK: 
mitogen activated protein kinases, GTP: guanosine triphosphate, GDP: guanosine diphosphate) 
 
Upon ligand activation of 5-HTR, a conformational change occurs at the cytoplasmic region 
of the receptor, which exposes Gα, Gβ & Gϒ   subunits along with the bound GDP and they 
(G protein subunits) dissociate from 5-HTR upon exchange of GDP to GTP by Gα subunit. 
Upon further conformational change during the dissociation from G protein, more AA 





residues from the receptor get exposed, which then undergoes phosphorylation via G 
protein-coupled receptor kinases (GRKs), which then recruits β-arrestin, leading to 
receptor internalisation process in a clathrin mediated fashion and the signalling can still 
be continued via MAPK activation during the receptor internalisation (52, 56, 57, 59, 69, 
74, 75). 
 G protein mediated pathways 
We still lack a complete understanding of the molecular downstream mechanisms of 
different 5-HTR subtypes, however based on the available information from various 
published articles, we can assume that there are several possible G protein mediated 
pathways (especially Gq & Gs mediated pathway have unique recruiting molecules), and 
different ligands induce conformational change in a unique way, which in turn leads to 
exposure of different AA residues at the cytoplasmic region of 5-HTR, and the subsequent 
signalling are tissue specific and effector protein specific. These cell signalling can bring 
about changes in the flow of ion channels as well as bringing changes at the DNA induced 
cellular level changes, which could be at both physiological level or functional level changes 
of the cell, which is depicted in Fig. 1.24 (59). 
 
 







Figure 1.24 Serotonin receptor signalling mechanism via G protein mediated pathway. (GIRKs: G protein-
coupled Inwardly-Rectifying potassium ion channels (hyperpolarises the cell when activated by βϒ subunits of 
G protein), PLC: Phospholipase C (upon activation by Gα subunit of G protein, PLC splits (via hydrolysis) PIP2 
into IP3 and DAG), PIP2: Phosphatidylinositol 4,5-bisphosphate, IP3: Inositol 1,4,5-trisphosphate (enters 
cytoplasm and binds to IP3 receptors on smooth endoplasmic reticulum to release Ca2+), DAG: diacylglycerol 
(activates PKC), PKC: Protein Kinase C (phosphorylates cytosolic proteins), AC: Adenylyl cyclase (converts ATP 
to cAMP), ATP: Adenosine Triphosphate, cAMP: Cyclic Adenosine Monophosphate (activates PKA), PKA: 
cAMP-dependent Protein Kinase A (upon activation catalytic component separates from its regulatory 

















1.6 Aims and objectives of the research 
 
5-HT has affinities for a wide range of 5-HTR subtypes, including 5-HT1B. Anti-migraine 
drugs have the potential to mimic 5-HT at their receptors, i.e. at the 5-HTR due to 
molecular structural analogies. Though these drugs can act as 5-HT or DA mimics, their 
MOA as anti-migraine is still not clear, therefore, our aim of this research is also to throw 
some light in this area by finding out if these drugs can act as mimics and bind to 5-HT 
receptors and correct the irregularities in 5-HT or DA neurotransmission leading to 
relieving the symptoms in migraine. 
 
 Aims of the research  
To study insilico, the structural analogy of anti-migraine drugs to 5-HT/DA, and their 
possible interactions at 5-HT/DA receptors due to their common functional groups and 
molecular structures.  
 Research objectives & study design  
Using molecular modelling techniques - ChemBio3D, Pymol & Schrödinger;  
I. Compare molecular structures of anti-migraine drugs (triptans & non triptans) 
with neurotransmitters such as 5- HT or DA and study the role of structural 
analogy between the drugs and neurotransmitters. 
II. Explore the neurotransmitter’s role in migraine using online search engines.  
III. Download X-ray crystallographic coordinates of 5-HT/DA receptors  
IV. Test docking of anti-migraine drugs as ligands to 5-HT/DA receptors and study 
the differences in interactions (in terms of binding energy, conformational 
changes, glide scores etc.) v/s their natural ligand.  
V. Study, natural ligand-receptor crystal structures of 5-HT/DA receptors as 
references, possible interactions in their binding cleft & molecular conformations 
of 5-HT receptor complex.  





VI. Validate the above in silico tests and Use appropriate references for the study 
design.  
VII. Determine if anti-migraine drug treatment can be made more efficient by 
activating a 5-HT receptor and would a successful docking experiment can throw 
some light in the dark areas of understanding the migraine disorder. 
VIII. Can this research lead to a better understanding of the migraine disorder and 
thus perhaps opening more possibilities for better treatment options such as 
structure-based drug design?  
1.7  Research hypothesis in relation to the structural analogy concepts 
 
• I propose through this research that a disturbance in the DA and 5-HT homeostasis 
is assumed as we don’t have enough scientific evidence to derive this as a definite 
cause based on the findings as explained above, as I assume increased DA 
availability in the brain could be implicated in the development of Migraine, which 
could be aggravated by the phenomenon of molecular mimicry of these 
neurotransmitters to specific dietary AA (from chapter 1, Fig 1.1, also, please refer 
sec.1.4) along with other genetically predisposed factors, which have contributed to 
a lower threshold to migraine specific triggers, activates the migraine response and 
that anti-migraine drugs which mimic serotonin is partly able to correct this 
dyshomeostasis by activating certain 5-HTRs and able to relieve the symptoms.  
• To simulate this molecular structural analogy, I have used insilico docking 
experiments with x-ray crystallographic structures of active 5-HTRs bound to 
ergotamine and anti-migraine drugs to dock in the ligand binding cleft (LBC) by 
replacing the bound ligand and studied the binding energies to see if they favour 
the interactions in a similar way within the permissible regulations of molecular 
binding dynamics. More details of this experiment can be found in the following 
chapter.






1.8 Methods  
 
  
1. Prepare, a list of anti-migraine drugs commonly prescribed in migraine, and 
investigate the potential molecular mimicry between these drugs/or their 
metabolites (using published metabolism studies) and 5-HT/DA using online 
search tools such as University of Canterbury library online search tools, google 
scholar, google search, and online chemical information databases such as 
pubchem etc.  
2. Use online data bases such as the protein data bank (PDB) 
(https://www.rcsb.org/) for appropriate protein receptors, and study the binding 
cleft using the natural ligand molecular structures and other published research 
documents to refer and  verify interactions. Download X-ray crystallographic 
coordinates of 5-HT/DA receptors (include only important sub types, e.g., ERG-5-
HT1B receptor) and upload to Pymol/Schrödinger, locate their binding clefts with 
ligands and study the ligand – receptor binding mechanisms.  
3. Attempt to dock anti-migraine drugs, in the binding cleft of 5-HT/DA receptors, 
using Schrödinger software. Determine binding mechanisms; use measurements 
and scoring functions such as glide factors and binding energy.  
4. Study reference structures, if no bound natural ligand-receptor available, create 
one using methods from Schrödinger (remove ERG in ERG-5-HT 1B receptor 
complex, and dock natural ligand)  
 
1.9 Overview of ‘Glide’ program and ‘Maestro’ interface from Schrödinger platform 
 
Schrödinger provides a next generation web-based platform, with a diverse set of software 
tools designed for biochemical research and application. Maestro as an interface, organizes 
access to the interactive tools for use in materials science projects within Schrödinger (76). 





Features of Maestro include various tool bar options, menu bar options, work space 




Glide is a grid-based ligand docking software program with scientific methods and 
computational procedures. Glide can be run to create several ligand conformations, using 
ligand preparation protocol within the protein preparation wizard. 
in a project designed by the user, one can generate several possible ligand conformations 
as poses of the ligand using ligand preparation protocol, where a rotatable group (Fig.1.25) 
will be identified automatically and saved as a new entry of ligand in a project and each 
entry can be used for docking experiment. Each ligand must be a single molecule, while the 
receptor may include more than one molecule, such as a protein. The ligand conformations 
(Fig.1.25) that Glide generates is docked with the receptor, using glide commands, after a 
series of receptor preparation procedures and the receptor-ligand interaction dynamics 
can be studied using the results output data obtained after running the protein 
preparation wizard protocol.  
 
 Glide: Protocols 
Use appropriate work directory to save experiment results before starting the 
experiments. Following are the various stages of the experiments 
1.9.2.1 Part A: Preparation of receptors 
From the protein preparation wizard tab download the receptors using the PBD code (such 
as 4IAQ, 4IAR etc) and study the receptor with a bound ligand at the Ligand Binding Cleft 
(LBC) of the receptor. 
Use Import and Process options from the software to prepare the receptor and trace any 
• missing side chains 
• missing loops 
Use Review and Modify options to trace water molecules left in the protein after pre-
processing, water molecules can be important in ligand binding especially when they are 





near the LBC. On successful binding of the ligand, displacement of water molecule can be 
observed or sometimes they engage with the receptor or ligand to contribute to the 
stability of conformations via hydrogen bonding. Hence if water molecules are there in the 
LBC they may have a role sometimes in maintaining a receptor-ligand complex, hence no 
need to remove them. However, in distant side chains where you don’t expect an 
interaction, they can be removed to save time in computational calculations. 
 
H-bond assignment can be refined to minimize hydrogens of altered species (many missing 
sidechains will be detected to fill the valences appropriately) and optimized for their 
rotational options. Restrained energy minimization option is selected to aid minimum 
energy level calculations for scoring functions  
 
1.9.2.2 Part B: Generation of the grid file 
This part of the experiment defines the receptor grid where the appropriate ligands of 
choice will be docked. 
By using receptor grid generation option, the receptor and ligand can be appropriately 
identified within the LBC, and the already bound ligand can be removed from the LBC. 
A receptor grid box will be generated at this stage. 
Rotatable groups within LBC can be identified and if required can be made rotatable, 
however the receptor backbone structure will be rigid in the whole experiment. 
A grid file will be generated, and this will be used at a later stage of the experiment. 
 
1.9.2.3 Part C: Ligand preparation 
Use the 2D sketcher to draw the ligands for docking experiments.  
The newly created ligand entry can be saved in the experiment project table with 
appropriate labelling. 
 The 2D structure can be converted to 3D in the workspace and can be explored to study 
the structural analogy. LigPrep tool can be used to prepare the ligand and generate several 
numbers of poses. Limiting the poses to a maximum of 20 would be enough to generate 
several low energy level conformations suitable for docking. This process will generate a 
file recording the ligand poses which will be used later during the docking process. 





1.9.2.4 Part D: Ligand docking 
 
Using the ligand docking tool, the receptor and the ligands prepared earlier will be used for 
docking experiment and an appropriate file will be generated. Several settings can be 
selected or removed such as tracking and using the appropriate files and using certain 
precision modes and output file descriptions etc. Several of the settings are appropriate to 
leave as default. 
 
1.9.2.5 Part 5: Analysis of docking results 
 
Using the XP visualiser option one can study the result table window and the various 
scoring functions. Select the ligands which have docked best by comparing the docking 
scores/glide scores. Examine the binding energies of each of the amino acid residues.  
One can look at the 3D interactions by opting for the several display options and study the 
structures and their interactions in the display workspace. Workspace gives a range of 
options such as pi-pi interaction and hydrogen bonds, as well as the good, bad and ugly 
interactions too. To look at 2D interactions simply click on the ligand interaction diagram 
tab which will highlight the residues and selected display interactions. The images can be 


















1.10 Ligand docking experiments using Schrödinger 
• Limited number of flexibilities of rotatable groups 
During the receptor grid generation and the ligand preparation stages there is a scope of 
allowing selective rotatable groups to be rotatable, which is not enough to mimic the real 
biological scenario, hence there will be some limitations to the reproducibility of 
experiment results in real biological systems. However, this experiment gives a picture of 
some reliable understanding of what we can expect in a ligand-receptor interaction with 
detailed binding energy data from several aspects.  
 
There could be several conformations possible at the time of binding, which will depend on 
several electrostatic forces, however, some of this is captured in ligand, by generating 5 to 
10 conformations per ligand and a few more at LBC of receptor residues (Fig.1.25).  
 
 
Figure 1.25 An example of rotatable groups in a molecule 
As illustrated in Fig.1.25, each ligand is identified with a rotatable group by considering 
energy minimised poses by the software itself.  
• Ligand selection criteria 
Selected a list of anti-migraine drugs based on the current prescription trends, using online 













 Below is a list of ligands (Table 1.1) used in the docking experiment; 
1. Active gabapentin 2. Amitriptyline 
3. Aspirin 4. Dopamine 
5. Droperidol 6. Eletriptan 
7. Ergotamine 8. Gabapentin 
9. Metoclopramide 10. Metoprolol 
11. Nortriptyline 12. Propranolol 
13. Serotonin 14. Sumatriptan 
15. Topiramate 16. Verapamil 
17. Metabolite of verapamil 18. Metabolite of amytriptyline 
19. Metabolite of nortriptyline 20. Metabolite of norverapramil 
21. Metabolite of aspirin 22. Metabolite of 
metaclopramide 
23. Metabolite of metoprolol 24. Metabolite of propranolol 
25. Paracetamol 26. Metabolite of paracetamol 




31. Loxapine-antagonist 32. Risperidone-antagonist 
Table 1.1 List of ligands used in the docking experiment. 
• Receptor selection criteria 
X-ray crystallised protein structures of 5-HTRs were used in this docking experiment. Below 
is a list (Table 1.2) of these receptor’s ’ PDB ID’s along with their 5-HTR subtype 
classification; 
1.  4IAQ-5HT1B 
2.  4IAR-5HT1B  
3.  4IB4-5HT2B  
4.  4NC3-5HT2B  
5.  5AIN-5HT3  
6.  5TVN-5HT2B  
7.  5V54-5HT1B  
8.  6BQG-5HT2C  
9.  6BQH-5HT2C  
10.  6CM4-D2   
11.  5TUD-5HT2B 
Table 1.2 List of receptors used in the docking experiment 
• Receptor and ligand preparation 
Rigid receptor conformations bound to a ligand were used for the docking experiment 
where a ligand of choice with varying rigid conformations were used. These ligand 





conformations were generated at the time of ligand preparation stage. Ligand docking were 
performed using Glide in extra precision (XP) mode. During receptor grid generation 
process, selected residues were identified by the program to allow rotation of hydroxyl and 
thiol groups.  
        
Ligand preparation program were carried out with inbuilt following conditions; 
 
 I. All structures must be three-dimensional (3D). 
 
 II. They must have realistic bond lengths and bond angles. 
 
 III. No molecules with covalent bonds to the receptor. 
IV. No accompanying fragments, such as counter ions and solvent molecules. 
V. All atoms must be with filled valences of electrons and no missing hydrogens. 
VI. Protonation state must meet the criteria appropriately considering pH values  
around 7 in real biological systems, for example, carboxylic acids should be  
deprotonated, and amino groups get protonated considering their pKa values.  
VII. A neutral aliphatic amine group can act as a hydrogen-bond acceptor without  
incurring any penalty. 
VIII. Protonation is crucial when receptor site is a metalloprotein. 
IX. All compatible formats including PDB is converted to Maestro format during any import 
processing, to facilitate Glide jobs. 
 
• Receptor grid generation 
In the receptor structure, an already bound ligand is selected to be identified as a ligand 
molecule within the ligand/receptor complex which is then distinguished from the receptor 
and removed after grid generation. The grid generated will appear as an enclosed box 
region of LBC, represents the volume of the protein for which grids will be calculated. 
Under Van der Waals radii scaling option, receptor atoms defined as nonpolar by a partial 
charge threshold during ordinary docking process is set by default values of scaling factor of 
1.00, which means that the receptor atom radii are not changed, if this factor is changed 
then van der Waals radii of nonpolar receptor atoms are multiplied by this value. Some non-
polar receptor atoms may attain partial charges during the docking process, and this can be 
made less significant as recommended during the energy scoring process by assigning a 





slightly higher partial charge threshold value such as 0.25 to consider it to be non-polar, as 
Van der Waals radii scaling option is performed only on nonpolar atoms. 
 
• Glide docking and results 
 
Each ligand conformation is docked in the LBC, and scored in terms of its E-model, which 
comprised of significant weighting of the force fields and energies. Each Ligand, during 
conformation generation process described earlier, is represented by a set of core 
conformations, which depends on the number of rotatable bonds. For each core 
conformation, an exhaustive search of possible locations and orientations is performed at 
the LBC of the protein. Glide positions the ligand if there is a good enough match, and 
examins the placement of atoms that lie within a specified orientation of the ligand 
diameter, without many steric clashes with the receptor. The interactions of all atoms 
capable of making hydrogen bonds or ligand-metal interactions with the receptor are scored 
as subset test. The scoring depends on the ligand conformation and energy minimisation at 
recognised contacts within LBC. The scoring also recognizes favourable hydrophobic, 
hydrogen-bonding, & metal-ligation interactions, and penalizes steric clashes. 
Finally, the selected poses are re-scored using Glide score based on Chem score, by adding 
other rewards and penalties devised by Schrödinger, for example, penalties for 
electrostatic mismatches known as buried polar terms, amide twist penalties, hydrophobic 
enclosure terms, and excluded volume penalties etc. 
 
An example of Glide score (G score) calculation for a ligand entry (conformation specific) is 
as shown below (77); 
Glide score = 0.05*vdW + 0.15*Coul + Lipo + Hbond + Metal + Rewards + RotB + Site 
 
(vdW: Van der Waals energy; Coul: Coulomb energy; Lipo: Lipophilic;  
HBond: Hydrogen-bonding; Metal: Metal-binding; Rewards: Rewards and penalties; RotB: 
Penalty for freezing rotatable bonds; Site: Polar interactions in the active site) 
 
The electrostatic forces and binding energies considered for scoring purposes were 






1. Van der Waals energy: calculated with reduced net ionic charges on groups with 
formal charges, such as metals, carboxylates etc.  
2. Coulomb energy: calculated with reduced net ionic charges on groups with formal 
charges, such as metals, carboxylates etc.  
3. Lipophilic interactions: rewards favourable hydrophobic interactions.  
4. Hydrogen-bonding: depend on whether the donor and acceptor are neutral, one is 
neutral and the other is charged, or both are charged.  
5. Metal-binding:  interactions with anionic or highly polar acceptor atoms are 
included. If the net metal charge in the apo protein is positive, the preference for 
anionic or polar ligands is included and if the net charge is zero, the preference is 
suppressed.  
6. Rewards and penalties: such as buried polar groups, hydrophobic enclosure, 
correlated hydrogen bonds, amide twists, and so on.  
7. Penalty for freezing rotatable bonds.  
8. Polar interactions: polar but non-hydrogen-bonding atoms in a hydrophobic region 
are rewarded.  
 
• Analysing ligand interactions using the docking results 
 
Various scoring parameters available from the glide docking experiments for ligand 
interaction studies are; 
 
1. Emodel: combines the Glide score and the nonbonded interaction energies. 
Generally used to rank each ligand entry within a project designed by the user.   
gives an indication of best-docked structure for each ligand. The score combines the 
energy grid score, the binding affinity predicted by Glide score, and in the case of 
flexible docking, gives the internal strain energy specific to conformational-search 
algorithm.  





2. Coulomb-van der Waals interaction-energy score (Glide energy): formulated to avoid 
overly rewarding charge-charge interactions. This score is intended to be more 
suitable for comparing the binding affinities of different ligands.  
3. Docking score: is the Glide score supplemented by Epik state penalties (state penalty 
for ligand protonation and tautomerization) and strain corrections in the case of 
induced fit docking 
4. Glide score: as an estimate of the binding energy including hydrogen bonds, 
hydrophobic enclosure reward contributions and factors rewarding, or penalizing 
interactions known to influence ligand binding.  
5. Ligand Interaction Diagram: a schematic representation of hydrogen bonds and - 
interactions. 
 
Glide can reduce the time and cost involved in finding the best ligand search where different 
rotamer groups to be optimized one at a time for a given core conformation and location of 
the ligand. Glide offers performance advantages which allows large libraries to be screened 
at an affordable computational cost. The primary purpose of Glide program is for screening 
large numbers of ligands bound to a largely rigid receptor models (77). Glidescore (Gscore) 
is an empirical scoring function designed to maximize separation of compounds with strong 
binding affinity from those with little or no binding ability. As an empirical scoring function, 
it is comprised of terms that account for the physics of the binding process including a 
lipophilic-lipophilic term, hydrogen bond terms, a rotatable bond penalty, and contributions 




















2 Experiment results 
The insilico modelling studies were carried out with Glide software program using Maestro 
interface from Schrödinger (Schrödinger Release 2017-1: Maestro, Schrödinger LLC, New 
York, NY, 2017 & Schrödinger Release 2018-3: Glide, Schrödinger, LLC, New York, NY, 
2018). Glide allows several options for the ligand docking experiments such as, specifying 
the receptor grid for docking, making ligand settings for glide docking, making basic 
settings for glide docking, constraining ligand docking to a specified core etc. Some of the 
above options were opted and further specified while running the program as mentioned 
below; 
• The Glide mode opted for ligand docking were of extra precision (XP) mode, which 
helps in visualising some of the ligand interactions. 
• Van der Waals radii scaling for ligand atoms was set to the default values with 
scaling factor to 0.8 and partial charge cut off to 0.15 (to soften the scoring of the 
for non-polar parts of ligands). 
• Opted for flexible ligand sampling, as this gives better docking chances over rigid 
ligand.   
• Opted to add epic state penalties to docking score, where epik uses empirical 
Hammett and Taft relations to predict pKa values by recognizing functional groups 
that may be ionized by the addition or removal of a proton based on the pH values 
of the solution. 
• Ligand core restricted to reference position of the ligand already bound in receptor. 
• Restricted ligand interaction scoring within 12 Å of grid centre. 
• Rigid receptor conformations were used with some flexibility allowed only to 
selected rotatable groups. 
The insilico experiments were carried out using 32 molecules, most of them known to be 
prescribed as anti-migraine drugs, by general practitioners (GPs) for the treatment of 
migraine. These molecules were docked as ligands to a set of 10 known 5-HTRs and a single 
DA receptor subtype known as D2. X-ray crystallographic structures of protein receptors 
such as proteins with PDB ID; 4IAQ, 4IAR etc., were downloaded from online protein data 





bank. These protein receptor structures had at least one ligand bound to them, when they 
were crystallised, and this ligand-receptor complex and their interactions were identified 
as reference LBC and the bound ligand was identified as reference ligand during the insilico 
docking study. The 32 ligand structures, used for docking study, were built using 2D 
sketcher option from Maestro and were entered to a new project. Both ligands and 
receptors were prepared using LigPrep and Protein Preparation Wizard options 
respectively from Glide. After identifying the LBC as explained earlier, a receptor grid was 
generated using the Receptor Grid Generation option from Glide. This receptor grid uses 
already bound ligand as a reference ligand core for docking the other 32 ligands of our 
choice, by replacing the reference ligand in the protein receptor within 0.1 to 1 Å 
tolerance.   
 
Glide program is generally used for screening applications for choosing preferred ligands 
from a pool of database of ligands. However, Glide can also be optimized for docking 
accuracies, which introduces some sensitivity to the receptor conformations studied for 
docking due to lack of receptor flexibility and is reflected in results as glide score (gscore). 
These ligands for the docking studies were built and prepared using LigPrep option from 
Glide, where a maximum of 20 ligand poses were generated. Some more details of ligand 
preparation and docking process are detailed in following sections. 
2.1 Protein and ligand preparation results 
 
At the time of receptor preparation, several residues were identified (Fig. 2.1) to fill with 
missing side chains (approximately 48 residues for 4IAQ), and during receptor grid 
generation several hydroxyl groups (or thiols) or hydrogen atoms at the LBC were made 
rotatable to facilitate ligand interaction (Fig. 2.2). Some examples of residues of 5HT1B 
receptor subtype with rotatable groups were; Tyr40, Tyr109, Ser127, Cys133, Thr134, 
Tyr208, Ser212, Ser334, Thr355, Tyr359 etc. and examples of residues with filled in missing 
side chains of 5HT1B receptor subtype were; Ile39, Met54, Arg76, Arg78, Arg114, Lys160, 
Lys164, Arg188, Gln189, Ser197, Glu198 etc. 






Figure 2.1 Above examples of Maestro window highlighting missing atoms detected by protein preparation 
wizard from Glide program for receptor PDB ID:4IAQ. The above displayed residues are examples of how we 
can locate different helices (Helix I/II/III) based on the residue number informations and study for their 
proximity to ligand for missing atoms of hydroxyl group or thiol groups.  











 Figure 2.2 Examples of rotatable groups selected 
for receptor PDB ID: 4IAQ from the Maestro 
window, based on its proximity from the helices 
identified (based on the residue numbering) to the 
ligand where an addition of hydrogen atom may be 
crucial in establishing a ligand interaction such as 
hydrogen bonding. 
 





2.2 Ligand docking results: G scores, docking scores & glide energy 
When Ligand Docking was set up from Glide, following options were selected (Fig. 2.3); 
• Precision set to XP mode 
• Ligand sampling set to flexible  
• Add Epik penalties to docking score 
 
Figure 2.3 settings of ligand docking experiments from the Maestro window using Glide XP mode precision 
selection and the selections for penalising the non-appropriate conformations and scoring parameters with 
the option of flexible ligand. 
                                        
                                            





              
     Serotonin (blue) overlaid to Ergotamine (red)             Serotonin (blue) overlaid to Sumatriptan (red)    
 
           
                Serotonin (blue) overlaid to Eletriptan (red) 
Figure 2.4 Striking structural analogy of serotonin (in blue) to anti-migraine drugs ergotamine, sumatriptan 
and eletriptan when overlaid. 
 
When anti-migraine drugs were overlaid to serotonin or dopamine, most of them showed 
a visibly hidden serotonin or dopamine in their molecular structures (Fig. 2.4). Ergotamine 
bound 5-HTRs downloaded from protein data bank (PDB ID: 4IAQ & 4IAR), probably 
indicate that ergotamine may be mimicking 5-HT in its receptors and can activate 5-HTRs 
due to its structural analogy to 5-HT, especially due to an indole ring present in them. This 
could be one of the reasons of its analgesic property when ergotamines are prescribed in 
migraine. Hence, we can propose that, the same could be true with most of the anti-
migraine drugs, and that they are either mimicking 5-HT or DA at their respective receptors 
and support the same assumption with the docking results of anti-migraine drugs to 5-HT 
& DA receptors.  
Hence, a molecular modelling study was carried out to explore the possibility of docking 
antimigraine drugs to 5-HTRs/D2 and tested if they can establish any desirable interactions 
to activate the receptors by recording their gscores in kcal/mol (Fig. 2.6). Interestingly all 





anti-migraine drugs tested had negative energy values (in Kcal/mol) for all the three 
different parameters such as gscore, docking score and glide energy (Table 2.1). 
Title Gscore Docking score Glide energy 
Serotonin -7.293 -7.293 -33.241 
Eletriptan -11.879 -11.877 -54.32 
Eletriptan -10.617 -10.615 -54.557 
Sumatriptan -10.079 -10.075 -49.693 
Ergotamine -10.295 -9.558 -62.744 
Amitriptyline -9.067 -9.064 -38.393 
Nortriptyline -9.007 -9.007 -33.466 
Ergotamine -9.021 -8.809 -64.636 
Ergotamine -9.432 -8.696 -55.856 
Droperidol -9.788 -8.676 -44.777 
Serotonin -8.2 -8.2 -32.824 
Dopamine -8.18 -8.18 -31.813 
Droperidol -8.192 -8.093 -46.966 
Propranolol -8.579 -8.065 -36.795 
(Metabolite) Nortriptyline -7.686 -7.686 -35.721 
(Metabolite-EHNT) 
Amitriptyline -7.546 -7.546 -36.941 
Verapamil -7.506 -7.505 -33.675 
(Metabolite) Norverapamil -7.452 -7.452 -53.056 
Metoprolol -7.364 -7.361 -40.044 
Metoclopramide -7.128 -7.123 -40.373 
(Metabolite) propranolol -6.838 -6.838 -39.129 
Droperidol -7.843 -6.731 -48.825 
(Metabolite-D617) 
verapamil -6.282 -6.282 -35.216 
Propranolol -6.498 -6.175 -37.733 
(Metabolite) Salicycluric 
acid -5.863 -5.863 -35.468 
(Metabolite) Metoprolol -5.78 -5.78 -43.011 
(Metabolite) 
Metoclopramide -5.727 -5.727 -36.818 
Gabapentin -5.674 -5.674 -14.042 
Topiramate -4.867 -4.867 -32.388 
Active Gabapentin -4.745 -4.745 -20.799 
paracetamol -4.034 -4.033 -27.746 
Paracetamol (Metabolite-
NAPB) -5.24 -5.24 -30.089 
Aspirin -3.503 -3.503 -20.571 
Table 2.1 Glide scores, Docking scores and Glide energies (units in Kcal/mol) for different molecules and their 
metabolites obtained after the insilico experiments of ligand docking to 5-HT1B (PDB ID 4IAQ) with Glide 
software from Schrödinger (Schrödinger Release 2017-1: Maestro, Schrödinger LLC, New York, NY, 2017 & 
Schrödinger Release 2018-3: Glide, Schrödinger, LLC, New York, NY, 2018). 






All anti-migraine drugs used in the insilico docking study had a negative gscore to 5-HTRs, 
and lower the Gscore, would mean more successful the binding to the receptors studied. 
Most of the anti-migraine drugs tested including eletriptan, ergotamine, and sumatriptan 
had gscores lower than the natural ligand 5-HT, indicating a better binding possibility to 
5HTRs (Fig. 2.7). Of all the ligands tested glide energies were lowest for Eletriptan and 
Ergotamine (Fig. 2.7 & 2.6), and docking scores were also lowest for these two along with 
sumatriptan (Table 2.1). However, at this stage we can’t predict how likely they behave in 
real biological systems. 
 
It is well addressed in the section 1.5.4 that 5-HT can regulate a wide range of signalling 
mechanism through 5-HT receptors and that their role in alleviating pain and inflammation 
in cephalic and peripheral nervous system and vascular regions is an interesting area to 
explore. When we explore the signalling mechanisms it is by now known that several 
residues which are crucial in recognising the conformational changes in the orthosteric 
binding pocket which spans around the transmembrane region to the extra cellular half of 
the receptor can act as micro switches to initiate a signalling mechanism. These signalling 
mechanisms recruit  signalling proteins at their cytoplasmic region of the receptor as 
explained in section 1.5.4 to 1.5.6, initiating a cascade of signalling pathway. 5-HT or other 
look alike molecules such as anti-migraine drugs may initiate these signalling mechanisms 
by interacting with certain residues at their extra cellular area of the receptor (78). Certain 
residues within the receptor are key to recognising the ligand by acting as microswitches 
are capable of initiating conformational changes and can extend these conformational 
changes by displacing the helices in the cytoplasmic region (Fig. 2.9 & 2.10), which exposes 
regions for coupling with secondary signalling proteins. Some of these microswitches are 
known as PIF, DERY, NPY motiffs. The DERY motiff comprises of residues from 5-HT1B are, 
Asp146, Glu309, Arg147, Tyr157 and from 5-HT2B are, Asp152, Glu319, Arg153, Thr89 (78). 
Further investigations in this regard will be discussed under ligand interactions section in 
this chapter, where a detailed ligand-receptor complexes post docking experiments in 
Maestro will be shared.  
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Fig. 2.6 continued to next page (94) 
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Fig. 2.6 continued to next page (95) 
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Figure 2.5 A) PDB ID: 4IAQ with bound Ergotamine (ERG) before docking experiment B) Eletriptan (ELE) post 
docking experiment to the same binding pocket C) Superimposed image of both ERG (in green) and ELE 
describing the conformational differences between both the ligands, and confirming docking at the same 
binding site D) ELE at the orthosteric binding pocket of 4IAQ, displaying salt bridge interaction (distance 2.8 
Å) to ASP 129, H-bond (distance 1.9 Å) with THR 134 and a Pi-Pi stacking (distance 5 Å) with PHE 331, also 
detailed ligand interaction diagram  in E & F. (5-HTRs used above are from online protein data bank with PDB 
ID: 4IAQ,and processed with Maestro from Schrödinger software platform) 
 






Figure 2.6 Insilico docking studies with Glide software from Schrödinger shows high potential for antimigraine 
drugs (when docked as ligands) to mimick 5-HT and be able to interact at binding sites of different 5-HT 
receptor subtypes especially for those with a G score (in kcal/mol) lower than that of 5-HT (as green trend 
line in above graph) itself, and one such molecule is Ergotamine (g score -11.8). Please note: as per 
Schrödinger g scores of -10 or lower usually represent good binding. However for hydrophobic interactions, g 
scores of -8 or -9 might be very good, and Glide XP tends to produce lower g scores (-12 or below),which 
depends on the van der Waals radii scaling factors (79, 80). 
 
Several repeats of the docking experiments were performed, where results were similar for 
similar ligand conformations. However, some repeats were set to perform with increased 
number of different ligand conformations than previosly set, along with a few more 
increased number of rotatable residues near the binding site, while generating receptor 
grid, which resulted in improved docking scores and gscores. Out of all the repeat results, 
the highest negative glide scores were selected for result analysis table (Table 2.1) as the 
intention was to get the data, indicating any possibility of establishing ligand interactions 





















Aspirin -4.547 -4.052 -5.195 -5.256 2.165 -4.908 -5.357 -4.401 -5.243 -4.584
Dopamine -8.701 -8.194 -8.379 -8.524 -11.465 -7.541 -9.287 -8.254 -8.904 -7.714
Eletriptan -11.879 -10.363 -6.149 -7.667 -13.933 -5.8 -10.912 -8.464 -4.874 -4.668
Ergotamine -10.295 -11.826 -12.518 -12.436 0 -8.733 -10.156 -10.086 -12.801 -4.372
Propranolol -9.148 -8.807 -9.943 -10.29 -3.22 -9.626 -10.711 -11.119 -7.929 -7.31
Serotonin -8.2 -7.414 -8.927 -8.834 -10.106 -6.466 -9.12 -9.326 -7.614 -6.975
































Figure 2.7 A) Glide scores (G scores) for a range of selected molecules, post insilico docking to 5HT1B 
receptors. G score of natural ligand, 5-HT and G score cut off value of -10 Kcal/mol are plotted as trend lines 
for comparison with other ligands. G score higher than or equal to 5-HT indicates a good binding, such as 
eletriptan and ergotamine. B) Comparison of Glide energy to both G score and Docking score shows penalty 
















































































































































































































































































































































































































































































Comparison of glide energy to g score & docking score 
of ligands after insilico docking to 5-HT1B receptor 
(4IAQ)
Gscore Docking score Glide energy
        A 
B 
Ligands 





scoring as mentioned in section 1.10, hence a negative score would still indicate a possible molecular 
interaction as the scores can be affected due to Van der Waal’s scaling factor set at the time of docking.  
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Figure 2.8  Superimposed images of 3 different active conformations of 5-HTRs with ergotamine 
ligand bound (4IAQ-green & 4IAR-grey) to 3 different active conformations (4NC3-5-HT2B-pink 
ligand). A) Superimposed structures of 5-HT1B receptors (5IAR-grey-4IAQ-green) and 5-HT2B 
receptor (4NC3-red) above with matching extra cellular half and differing conformations in the 
cytoplasmic region upon receptor activation by ligands B) perpendicular alignment of aromatic ring 
conformation of ergotamine ligand (pink) when overlaid from 4IAQ, 4IAR and 4NC3 (4IAQ-5-HT1B -
grey ligand, 4IAR-5-HT1B -green ligand, 4NC3-5-HT2B-pink ligand). The above protein structures are 
processed using Maestro interface from Schrödinger. (5-HTRs used above are from online protein 
data bank with PDB ID: 4IAQ, 4IAR and 4NC3 and processed with Maestro from Schrödinger 
software platform) 
A 






Figure 2.9 Active conformations of ligands in the LBC of 3 different receptors (4IAQ-5-HT1B -grey ligand, 4IAR-
5-HT1B -green ligand, 4NC3-5-HT2B-pink ligand), indicating conformation specific different signalling 
properties of 5-HTRs, such as the one observed with β-AR biased signalling with some ligands.  
 
It is known that certain 5-HTRs can stimulate cAMP activation wherein some inhibit the 
same via different receptor subtypes. 5-HTRs are still an extensively researched molecule, 
hence we lack complete knowledge of its different molecular signalling mechanisms. It is 
noticed that 5-HTRs, such as 5-HT2B can have ligand specific signalling where in they differ 
in recruiting seconday preteins such as some ligands can recruit both G-proteins and β-
arrestin equally while some recruit β-arrestin selectively (Fig.2.10) (54). Hence it would be 
interesting to note that extended binding pocket will be crucial in influencing this selection 
of different signalling pathways, as the ligand conformation difference is quite apparent in 
5HT1B and 5-HT2B when overlaid (Fig.5 (B & C). Hence with different anti-migraine drugs 
though they are successful insilico in establishing orthosteric and extended binding pocket 
interactions, it would be difficult to establish which molecular signalling pathways they can 
trigger in real biological systems (section 1.5.4 to 1.5.6) and this would be an interesting 
area to explore. 










Table 2.2 Best values of Glide scores of various ligands with respect to the receptors that were docked in 
multiple experiments. Glide scores were sensitive to conformations of a ligand when docked and different 


























G scores of commonly prescribed anti-migraine drugs including 
paracetamol and aspirin
4IAQ
G score cut off
5-HT G score






Table 2.3 Glide scores of some selected ligands when they were docked into different receptors in multiple 
experiments. Negative scores indicate negative binding energy to the LBC of 5-HTR.  
Results of docking scores, g scores and glide energy values from the insilico docking 
experiments are illustrated in Table 2.1, 2.2, 2.3 and 2.4. The analysed results are 
illustrated in Fig. 2.6, 2.7, 2.8, 2.9, 2.10 & 2.11. Molecular mimicry of antimigraine drugs to 
5-HT is illustrated in Fig. 2.4, which may have influenced in their binding to 5-HTR receptors 
when insilico docking experiments were carried out and resulted in good binding scores 















































Figure 2.11  Table 2.4 Glide scores of ligands to 2 specific receptors of 5-HT1B known 
by their PDB ID: 4IAQ & 4IAR. 
 





2.3 Ligand interactions 
 
Table 2.5 Glide emodel scoring is useful to learn the favourable ligands to a given LBC investigated. As 
expected ergotamine is the best fit according to the glide emodel score in the above table, followed by 
norverapamil, eletriptan, droperidol and sumatriptan. PDB ID: 4IAQ is used for the docking results above. 
Natural ligand 5-HT had lower scores compared to the above-mentioned molecules and had a negative 
binding energy as indicated by glide energy to establish favourable interaction to the LBC of the receptor. 
 
Glide docking experiment gives a detailed output of results as in Table 2.5, which helps to 
study the ligands and compare them based on different scoring parameters. If ligands are 
not appropriately protonated before docking experiment such as carboxylic acids should 
be deprotonated and aliphatic amines should be protonated, which was not done in this 
experiment while sketching the ligands instead used LigPrep to generate required 
protonation states based on pH 7 +/- 2, (Fig. 2.16). Ligands did have neutral aliphatic 
amines which could have improperly acted as a hydrogen-bond acceptor in the docking 
calculations or could occupy a hydrophobic region without incurring any penalty that XP 
Glide docking would have assessed if the amine group had been properly protonated. The 
above error could have happened in this experiment as, ligands were not screened 
appropriately to make sure they were protonated or deprotonated depending on the pH of 
the biological solution which is approximately at 7 (or 7.4 in some published trials). This is 
especially crucial in metalloproteins, however the proteins we studied were not 
metalloproteins. 
 
AAs generally have two functional groups in them, such as an amino group and a carboxyl 
group with different pKa values to each functional group. Depending on the pH of the 
medium where they are existing and the net charge of the functional groups they carry 
would give the AAs a polarity or net charge. In real biological solutions where a pH is 
approximately 7, the functional groups in AAs can co-exist in both a deprotonated and a 
Title Entry ID glide gscore docking score glide emodel glide energy glide evdw glide ecoul XP GScore State Penalty glide rmsd to input
Eletriptan 2 -11.21 -11.209 -73.235 -48.435 -43.118 -5.317 -11.21 0.0016 34.225
metabol Norverapramil 3 -10.513 -10.512 -80.257 -53.306 -46.453 -6.854 -10.513 0.0005 37.185
Sumatriptan 5 -10.238 -10.234 -68.035 -48.276 -38.276 -10 -10.238 0.0039 33.917
metabol EHNT-Amytryptl 6 -9.964 -9.96 -56.181 -41.379 -33.072 -8.307 -9.964 0.0034 33.995
metabol D617 verapamil 7 -9.658 -9.658 -46.328 -35.821 -20.806 -15.014 -9.658 0 35.587
metabol EHNT-Amytryptl 8 -9.587 -9.584 -51.039 -40.149 -30.644 -9.506 -9.587 0.0034 32.461
metabol propranolol 9 -9.528 -9.194 -57.951 -43.43 -31.936 -11.494 -9.528 0.3346 32.63
Ergotamine 13 -9.125 -8.947 -84.972 -59.729 -54.137 -5.592 -9.125 0.1781 33.218
metabol propranolol 15 -9.21 -8.876 -56.299 -42.039 -31.888 -10.151 -9.21 0.3346 32.534
metabol metaclopramide 19 -7.914 -7.913 -52.615 -38.246 -26.44 -11.807 -7.914 0.0007 32.206
Droperidol 24 -8.376 -7.264 -73.836 -47.98 -43.449 -4.53 -8.376 1.1122 38.049
Serotonin 23 -7.419 -7.419 -43.976 -31.753 -23.11 -8.643 -7.419 0 33.085





protonated ionic form depending on the pKa of the functional groups and the net electric 
potential combining all the functional groups will decide the net charge of the AA. 
Zwitterionic forms of AAs exist at specific pH, where the net charge of all functional groups 
become zero, which is a state called the isoelectric point of an AA. The functional groups of 
AAs could exist in ionic form even during isoelectric point of an AA. The pKa values for 
amines and hydroxyl groups are generally higher than the pH of biological solutions (which 
is approximately pH 7), and for acids such as carboxyl groups would be lower than pH 7. 
When pH of the medium is equal to the pKa of the functional groups an equilibrium will 
exist where a deprotonated form of the AAs will be equal to the protonated form of AAs.  
 
The ionic forms of AAs resulting from both protonation and deprotonation (Fig. 2.18), as 
the neutral forms of AAs are very rare, will participate in a chemical reaction with other 
molecules such as ligands resulting in weak reversible chemical bonds such as ionic salt 
bridges, hydrogen bonding, and more weaker interactions involving mild electrostatic 
potential differences such as van der Waals forces and pi-pi stacking forces and in some 
instances strong irreversible chemical bonding such as covalent bonding can also be 
formed which typically involves a higher binding energy such as 50 to 150 Kcal/mol. The 
relationship between pH and pKa can be expressed using the Henderson-Hasselbalch 






 Ka = [H+] [A-]     
           [HA]     
Figure 2.12 Relationship of dissociation constant (Ka), pH & pKa expressed using the Henderson-Hasselbalch 
equation. Where the concentrations of acid base chemical species expressed as HA, and their dissociated 
ionic forms A−, and H+ are in equilibrium in a buffer solution, and the dissociation constant as Ka.  
 
The glide energy values from this experiment are indicative of weaker molecular 
interactions between ligands and 5-HTRs, hence the ligand interactions established after 
pKa = -log10 (Ka) 
             
pKa = pH - log10 [A-] 
                           [HA]     
             





the docking experiment would give reversible molecular bonding such as salt ionic bridge 
or hydrogen bonding interactions, and more weak interactions such as van der Waals 
interactions & pi-pi stacking interactions. These interactions can be studied in detail using 
ligand interaction diagrams. 
 
Figure 2.13 LigPrep window where ionization state was selected to generate possible protonation states for 
ligand to facilitate docking with appropriate energy levels. 
 
                                  
 
 
Protonated state at low pH                      Zwitterionic state at pH 7                    Deprotonated state at high pH 
Figure 2.14 Example of a protonated and deprotonated forms of an AA. Protonated state at low pH refers to 
the functional groups having a higher pKa than the pH of the solution medium and vice versa when it is 
deprotonated at high pH, i.e., the functional groups having a lower pKa than the pH of the solution medium. 






Some of the ligand interactions from the docking experiment carried out, using the 5-HTR 
template 4IAQ is illustrated using the docking results for selected molecules in the 
following sections.  
 Receptor details: 4IAQ 
The molecular details of the receptor protein at the time of download are; 
•  Total Structure Weight (Molar Mass): 46100.71  
• Atom Count: 2795  
• Residue Count: 403  
• Unique protein chains: 1 
• Molecule: Chimera protein of human 5-hydroxytryptamine receptor 1B and E. Coli 
soluble cytochrome b562 
• Protein: 5-HT1B (serotonin receptor) with bound ergotamine 
• Mutations: 4  
• Gene Names: cybC, HTR1B (HTR1DB) 
• pH: 8.7 
• Temperature: 293K 
• Ligand interaction: Dihydroergotamine 
However, the above details were changed slightly after protein preparation process using 





Table 2.6 Screen shot tables from Maestro window displaying details of residues and atoms of the receptor 
4IAQ. A) The details as per Maestro before processing B) The details as per Maestro before processing. The 
missing atoms were added by the software at the time of processing changed from 2800 atoms to 6345 
atoms and the number of residues changed from 373 to 394. Hence the information obtained from the PDB 
website and Maestro is different, and since Maestro is an advanced software the above information may be 
more reliable regarding the receptor details. 






Figure 2.15  A) Ligand interactions of dihydroergotamine with receptor 4IAQ. B) Ligand interactions of 
ergotamine with receptor 4IAR. These Images are downloaded from online protein data bank web site, where 
the x-ray crystallographic receptors 4IAQ and 4IAR are listed in bound active conformations (77, 81). The 
above interactions are indicative of forming a salt bridge and a hydrogen bond at the LBC.  
 
 Ligand interactions: Eletriptan 
 
 
Title Entry ID glide gscore docking score glide emodel glide energy glide evdw glide ecoul XP GScore State Penalty glide rmsd to input




Figure 2.20 continues to next page (108) 


















Figure 2.16 Above images of Eletriptan docked at the LBC of 4IAQ using Glide software from Schrödinger. A) 
Ligand interaction diagram of eletriptan at the LBC of 4IAQ. B) Summary of results obtained for eletriptan 
post docking experiment with the receptor. C) Eletriptan establishing interactions at the LBC of 4IAQ post 
docking experiment. D) Dihydroergotamine overlaid to eletriptan at the LBC using Glide to display the core of 
ligand docking is same for both the ligands. 
Eletriptan as a drug is generally prescribed for the acute treatment of migraine. I used this 
drug for the docking experiment to study its interactions. 
Eletriptan was able to establish successful interactions with the receptor post docking, the 
details of interactions were (Fig. 2.21); 
• H- bond to THR 134, bond distance 1.8 Å, acceptor angle 1670 
• Salt bridge interaction to ASP 129, bond distance 2.5 to 2.8 Å  
C 
D 





• Pi-Pi stacking distance to PHE 330 was 5.4 Å, and to PHE 331 was 5.1 to 5 Å 
Rigid receptor conformation was maintained to receptor core within tolerance of 0.1 to 
maximum 1 Å.  
 
                                       
Figure 2.17 Expanded ligand interaction diagram of eletriptan at the LBC. 
 
 Ligand interactions: Norverapamil 
 
Norverapamil is an active metabolite of verapamil, known as a calcium channel blocker 
mainly used in the treatment of hypertension. Verapamil is also prescribed for the 
treatment of migraine to relieve the symptoms of hypertension. Norverapamil was 
successfully docked into the receptor (4IAQ), with interactions as below (Fig. 2.22); 
• H- bond to VAL 201, bond distance 2.1 Å, donor angle 1220 
• Salt bridge interaction to ASP 129, bond distance 4.2 Å  
• Pi-Pi stacking distance to PHE 331 was 5.2 Å 
•        Pi-cation interaction distance to TRP 125 was 6.3 Å 
 
 




















 Ligand interactions: Sumatriptan 
Sumatriptan is used as a migraine specific medication. The details of this molecule used as 




Title Entry ID glide gscore docking score glide emodel glide energy glide evdw glide ecoul XP GScore State Penalty glide rmsd to input
metabol Norverapamil 3 -10.513 -10.512 -80.257 -53.306 -46.453 -6.854 -10.513 0.0005 37.185
Title Entry ID glide gscore docking score glide emodel glide energy glide evdw glide ecoul XP GScore State Penalty glide rmsd to input
Sumatriptan 5 -10.238 -10.234 -68.035 -48.276 -38.276 -10 -10.238 0.0039 33.917
B 
C 
Figure 2.18 Screen shots of nor verapamil being docked as ligand at the LBC. A) Summary of 
results obtained for Norverapamil post docking experiment with the receptor. B) Ligand 
interaction diagram with arrows and straight lines indicating the contacts with the receptor. 




Fig. 2.23 continues 
to next page (111) 






Figure 2.19 Ligand interaction results of sumatriptan when docked to 5-HTR (PDB ID:4IAQ) A) Various scoring 
details of sumatriptan using Glide XP docking experiment B) Topographical mesh view of the ligand binding 
domain of the receptor with the ligand (in ball and stick representation) docked to the LBC. C) Ligand 
interaction diagram of sumatriptan at the LBC of 4IAQ receptor. 
 
Sumatriptan interacts with the receptor (Fig. 2.23) via; 
  
•        H- bond to ASP 129, bond distance 1.7 Å, donor angle 1220 
• H- bond interaction to SER 212, bond distance 2.1 Å  
• Pi-Pi stacking distance to PHE 331 was 5.1 Å 
 
 Ligand interactions: Natural ligand (Serotonin) 
 
In the absence of an active natural ligand bound conformation to study the receptor, the 
dihydroergotamine bound active conformation of the receptor gives an idea how a ligand 
would interact and possibly give some indication to compare the active form with an 
inactive conformation if generated.  
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Title Entry ID glide gscore docking score glide emodel glide energy glide evdw glide ecoul XP GScore State Penalty glide rmsd to input
Serotonin 23 -7.419 -7.419 -43.976 -31.753 -23.11 -8.643 -7.419 0 33.085
B 
C 
Figure 2.20 Above images of 5-HT post docking experiment results with 5-HTR (PDB ID: 
4IAQ) A) Results table. B) Ligand interaction diagram. C) Pose view of the ligand at the 
LBC of the receptor.  





5-HT interacts with the receptor (Fig. 2.24) via; 
  
•        H- bond to ASP 129, bond distance 2.1 Å, donor angle 920 
• Pi- cation interaction to PHE 330, bond distance 5.0 Å  
• Pi-Pi stacking distance to PHE 331 was 5.3 Å 
 
We may now know that ASP 129 interaction from the orthosteric binding pocket of the 
receptor is crucial in recognising the ligand, as the dihydro ergotamine bound structure of 
4IAQ involved interaction with ASP129. The extended binding pocket interaction involving 
Val 201 is missing with natural ligand interaction which may have contributed to low glide 
scores with 5-HT. This indicates the fact that 5-HT may have an on and off interaction at 
the orthosteric pocket whereas the dihydroergotamine had more stability at the LBC due 
to its interaction with extended binding pocket. He orthosteric pocket comprised mainly 
hydrophobic residues of Val 102, Tyr 359, Phe 330 and negatively charged Asp 129. Polar 































3 Discussion  
3.1 Validity of the insilico experiments 
Scoring functions used by the software Glide XP, is based on enforcement of the physical 
and chemical principles of science to a great degree.  The scoring methods are reliable due 
to its reproducibility and optimised evaluations of the scoring function for correctly docked 
compounds. However, the insilico results need to be validated with reproducibility of 
results in real biological experiments due to the possibility of errors in the absence of 
representing the real biological environment during its testing phase. However, with 
improved adaptation using the data from real biological systems with respect to the 
kinetics and the molecular dynamics energy of the participating molecules in a receptor, 
the interactions can be reproduced and studied for accuracy of results. The following 
possibility of errors and limitations need to be considered in validating the accuracy of the 
docking results; 
 
• Errors in binding mode predictions 
• Errors in accuracy of computational algorithms for docking and scoring results 
• The algorithms for initial screening and energy minimization are not yet fully 
optimized 
• Errors in correctly finding docked poses and rejecting false positives during 
screening processes 
• Complicated user training modules and exhaustive details in running the software 
• Not very user friendly due to many ambiguities to operations and procedures 
• Lack of enough data to support the validation of insilico results from in vitro to in 
vivo results by having a comparison of experiments with real biological set up to 
relate to the results. 
• Lack of receptor flexibility in studying the helical rearrangements post successful 
docking. 
• Receptor conformation is rigid in the experiment, which is specific for the 
previously docked ligand and in real biological environment due to potential energy 





differences between different ligand interactions the desired receptor 
conformations are unknown, hence even though the docking results are indicative 
of a successful binding, will change in real setting as the receptor molecules are 
highly dynamic and may interact differently with different conformations. 
• Glide tests several possible conformations for a given ligand, to the given rigid 
conformation of the ligand. 
• Limited flexibility can be applied by having a rigid back bone conformation for the 
receptor and some sidechain residues can be made rotatable, this may give some 
favourable docking scores for the docked ligand. 
Having considered all the possible limitations, the benefits outweigh the limitations; hence 
Glide is a good tool to explore, learn & evaluate the possibilities in predicting the molecular 
interactions and designing a suitable drug or a molecule. The binding energy calculations 
are very detailed (as discussed in section 1.10), and the scoring functions (section 2.3) are 
highly useful in predicting a successful binding in docking experiments. Some of the scoring 
functions that were considered for evaluating the docking experiments are already listed in 
the results chapter (section 1.10, 2.3 and 2.4). We have compared the Gscore results of a 
set of anti-migraine drugs post docking in the results section 2.3. All ligands tested had a 
negative Gscore and negative binding energies for that specific conformation of receptor 
and ligand. However, the chances of achieving this specific conformation in real biological 
solution is not known, for this we must do experiments in biological mediums.  
 
Lower the Gscore of a ligand, would mean more successful in binding to the receptor for 
that specific conformation of a receptor, many of the anti-migraine drugs tested including 
eletriptan, ergotamine, and sumatriptan had Gscores lower than the natural ligand 5-HT, 
indicating a better binding possibility to 5HTRs. Of all the ligands tested glide energies were 
lowest for Eletriptan and Ergotamine, and docking scores were also lowest for these two 
along with sumatriptan. However, at this stage we can’t predict how likely they behave in 
real biological systems and will the same receptor and ligand conformations will be 
achieved. 
 





The simplest mechanism of GPCR activation is based on a two-state conformational 
selection model of receptors, whereby the receptor exists in an equilibrium between active 
and inactive states; agonists shift the equilibrium toward the active, whereas inverse 
agonists shift the state to the inactive state (75).  There could be many intermediate 
inactive and active conformations possible for GPCRs (54, 56-58, 73-75, 82), hence knowing 
all the molecular features of active and inactive state conformations will help in designing a 
drug suitable to avoid off targeting. Signalling changes during active and inactive states can 
be measured using laboratory-based monitoring methods, which will be discussed later in 
this section. 
 
The research has met its objective in completing the insilico docking experiments using the 
anti-migraine drugs as ligands to 5-HTRs for the given specific receptor conformation. 
 
3.2 Comparison of molecular structures of anti-migraine drugs (triptans & non 
triptans) with 5HT/DA and their structural analogy 
 
As illustrated in Figure 2.4 and in section 2.3, popular antimigraine drugs such as 
ergotamine, eletriptan and sumatriptan had a striking structural analogy to 5-HT, this led to 
the understanding that anti-migraine drugs might be mimicking 5-HT in the serotonergic 
synapses and might activate some of the 5-HTRs on the post synaptic nerves, which might 
be contributing to its efficacy in migraine.  
 
 
 Research hypothesis in relation to the structural analogy concepts to tyramine 
 
In section 1.7, my research hypothesis stated that molecular mimicry of tyramine to DA 
could be implicated in the form of dyshomeostasis involving DA and 5-HT, and an 
assumption is stated as increased DA availability in the brain could be implicated in the 
development of Migraine. Some dietary sources of AAs contribute to increased availability 
of tyramine in the system, or the brain might be able to synthesise which is unknown. 
Thus, non-neurotransmitter monoamines from the system, such as specific dietary AA 





(section 1.4 from chapter 1 & Fig 1.1) may mimic monoamine neurotransmitters besides 
the other genetically predisposed factors and contribute to a lower threshold to migraine 
specific triggers. However, their availability in brain is limited to crossing the BBB, and 
tyramine is known to be present in the brain. Thus, a migraine response may be activated 
and that anti-migraine drugs which mimic serotonin is partly able to correct this 
dyshomeostasis by activating certain 5-HTRs and able to relieve the symptoms. To prove 
this assumption, insilico docking experiments (using Glide XP software) were carried out 
with x-ray crystallographic structures of ergotamine bound active 5-HTRs and anti-migraine 
drugs, to dock in a related manner by replacing the bound ligand. The results were 
analysed using the docking results to assess the possibility of activating 5-HTRs by anti-
migraine agents. 
 
Section 1.3.6 & section 1.4.7 have given an understanding of the monoaminergic system, 
their role in pain modulation, and especially serotonergic system which acts via on or off 
mechanism to regulate various aspects of neurogenic pain modulation. This concept of 
pain matrix and the role of monoaminergic system probably has a role in the symptoms of 




















3.3 Do the results from docking experiments indicate the possibility of anti-migraine 
drugs activating 5-HTRs? 
 
The insilico docking experiment results from section 2.3 and Table 2.1 gives a detailed 
analysis of the possibility of anti-migraine drugs activating 5-HTRs. The negative binding 
energies are indicative of the binding possibilities, however whether this interaction is 
enough to activate the receptor is a difficult question, considering the limited data 
available on the 5-HTRs. More so because the active conformation dynamics of the 
receptor is restricted due to the rigid receptor insilico docking. As the receptor 
conformation is best suited to the already bound ergotamine (ERM) ligand. Considering 
these limitations, the best possible approach to analyse the results would be; 
• To generate an insilico data of how a natural ligand would interact in the given rigid 
receptor conformation. 
• Compare the Ligand interactions of anti-migraine drugs to the natural ligand. 
interactions and the interactions of the already bound ligands from 4 IAQ or 4 IAR 
•  Study the binding energies to relate to the ligand interactions. 
Based on the above discussed criteria, 5-HT had only an orthosteric LBC interaction while 
the ERM had both orthosteric and extended binding pocket interactions, hence the docking 
scores were lower with 5-HT and higher with ERM. The key residue involved in the 
orthosteric binding pocket was a negatively charged Asp 129 and other mixed hydrophobic 
or polar residues. This makes the natural ligand most likely to be involved in a salt bridge 
interaction in real biological scenario since the amino groups will be most likely protonated, 
and the hydrophobic pocket will not like a polar state and will engage the ligand in a more 
weaker salt bridge interaction with a longer bond distance than a hydrogen bond. The anti-
migraine drugs were successful in most instances in establishing an orthosteric binding 
pocket interaction due to the amino group present in them and some interacted to the 
extended binding pocket like the ERM, resulting in a good score overall (high score of 
negative value) compared to 5-HT. Of all the anti-migraine drugs tested the best suited 
based on the scoring parameters were indicative of ergotamine, eletriptan and sumatriptan. 





In section 1.2.3 meta-analysis data of migraine treatment responses shows eletriptan and 
sumatriptan were successful in giving good treatment response. 
 Interactions critical in ligand recognition 
 
Comparing the interactions of natural ligand to ERM, some critical differences are in the 
extended binding pockets of 5-HTR subtypes. The orthosteric binding pocket seems to be 
common in all 5-HTR subfamilies differing only in the extended binding pocket. There is a 3 
Å outward shift at the end of Helix V, when we compare the extended binding pockets of 
5-HT1B and 5-HT2B. This difference is key to subtype selectivity in ligand recognition among 
all 5-HTR subtypes.   
Some of the receptor interactions critical for the LBC stability are; 
• Disulphide bridge between helix III and ECL2 (Cys 122 & 199 in 5-HT1B and Cys 128 & 
207 in 5-HT2B) is conserved to all 5-HTRs. This disulphide bridge stabilises the 
extracellular loop 2 over the ligand binding pocket near the extended binding pocket. 
 
 
Figure 3.1 LBC of superimposed images of 4IAQ and 4IAR. The disulphide bridge (in yellow ball and stick 
representation) between Cys 199 and Cys 122 highlighted in red circle, helps stabilizes the LBC in position as 









• Hydrogen bonding between Asp 352 (a ligand binding residue) and Tyr 40 (close to 
N terminus), indicating role of N terminus in ligand recognition in 5-HT1B (Fig. 3.2)  
 
 
Figure 3.2 A) Tyr 40 from part of N-terminus loop (in ball and stick representation) interacting with Asp 352 
(labels in black square boxes) from helix VII via a hydrogen bonding (highlighted inside red circle as black 
dotted line) close to the extended binding pocket of 5-HT1B, indicating the role of N-terminus in ligand 
recognition which is not observed with 5-HT2B. B) Extracellular regions of 5-HT1B with red circled area 
depicting the N-terminus loop interaction residue from helix VII and the yellow circled area highlighting the 
disulphide bridge from ECL2 to helix III. C) Extracellular region missing N-terminus loop interaction from helix 
I in 5-HT2B , and highlighting the yellow circled area of disulphide bridge common to all 5-HTRs. 




















• Hydrogen bonding between Asp 129 and Tyr 359 contribute to maintaining the 
narrow orthosteric binding pocket. 
•  
Figure 3.3 The hydrogen bonding (displayed as teal coloured dotted line inside the red circle) between Asp 
129 and Tyr 359 (labelled as black square boxes with residues in ball and stick representation) in the narrow 
orthosteric binding pocket, where the ligand is displayed in CPK representation. Asp 129 also interacts with 
the amino group of the ligand. 
• The 3 extra cellular loops (ECL) between the seven transmembrane helices of the 
receptor are displayed as ECL1, ECL2 and ECL3 in Fig. 3.4. The Ligand binding 
hydrophobic pocket of the receptor mostly formed by residues such as, Ser 212, Ala 
216, Thr 134, Cys 133, Phe 330, Phe 331, Trp 327, Ile 130, Asp 129, Tyr 359, Asp 
352, Thr 355, Phe 351, Trp 125, Leu 126, Val 200 (ECL2), Val 201 (ECL2), Thr 203 
(ECL2), Thr 209, Ser 334, Met 337, & Tyr 40 (N-terminus loop) are defined with a 
ball and stick representation in Fig. 3.4. These residues may differ between varying 
5-HTR subtypes at the extended binding pocket. Other published reports have 
shown similar results of 3 Å distance (Fig. 3.6) between more closer residues such 
Ligand 
H2O 





as in helix V in extended binding pockets and are found to be broader in 5-HT1B 
than 5-HT2B due to outward shift of helix V (54). 
 
 
Figure 3.4 Topographical view of the LBC image from Maestro along with a cartoon representation of the 
GPCR receptor on the left (drawn using Chemdraw software) depicting the seven transmembrane helical 
structure of the receptor with inbuilt labelling of some helices and extra cellular loops. Residues in ball and 
stick representation define the hydrophobic LBC region of the receptor 4IAQ, while the ligand is represented 
in CPK form. 
• The differences in binding pockets of t he2 different 5-HTRs were examined using 
the quick align method in Maestro. It was noticed that the Leu 46 in helix I of 5-
HT1B is displaced by 9.26 Å (Fig. 3.5) compared to the similar helix (Leu 54) of 5-
HT2B, hence the extracellular regions of 5-HTRs may differ by more expanded or 
contracted binding pockets depending on their subtypes, as the replacing residues 
can be different in respective helices. This difference could be studied with more 
flexible docking experiments to understand the receptor subtype selectivity to help 
















subtypes which could be one of the reasons of unwanted side effects with many 
drugs resulting in their withdrawal.  
  
 
Figure 3.5 Topographical view of the quick aligned receptors of 5-HT1B and 5-HT2B. A) Residues (Leu 46 of 5-
HT1B & Leu 54 of 5-HT2B) from helix I of the two different 5-HTRs in ball and stick representation shows the 
distance between the nitrogen atoms as 9.26 Å. B) Enlarged view of the helix 1 of the aligned receptors, 
showing part of N-terminus loop moving closer to the binding pocket indicating a role in recognising the 
ligand. Both the ligands from the aligned receptors are displayed in ball and stick representation indicating 
orientation is slightly different in both receptors as the binding pocket is more expanded in one than the 


















    
 
Figure 3.6 A) Topographical view of the extracellular helices of the aligned 5-HTRs with their respective 
ligands in CPK representation. B) Distance measured between the aligned residues, Thr 209 of the 5-HT1B and 
Met 218 of the 5-HT2B, shows 2.55 Å shift between the α-carbons from helix V. C) Close up view of the LBC 
with the distance measurement highlighted in red circle. 
                         
• A pi-pi stacking interaction observed between the indole ring of the natural ligand 
and the residue Phe 331, as well as a hydrogen bond along with a salt bridge 
interaction from the aliphatic amino group side chain to Asp 129 and a pi-cation 
interaction with Phe 330 was observed during docking experiments in the 
























Figure 3.7 Intra receptor and ligand interactions after docking 5-HT (in teal colour ligand) and eletriptan (in 
orange red ligand) with 4IAQ receptor. All key residues in grey ball & stick representations, black dotted lines 
represent H-bonding, teal dotted lines represent pi-pi interactions. A) Both ligands in overlaid view to depict 
similar interactions, blue dotted line from Asp 129 indicates a salt bridge interaction, green dotted line for pi-





















 Receptor features 
 
Figure 3.8 5-HT1B highlighting its extracellular region and the intracellular regions in 3D view. The middle non-
highlighted area is assumed to be embedded in the cell membrane region, hence known as transmembrane 
region. A cartoon image in the inset shows how the helices would look in a planar 2D view. 
All 5-HTRs have 7 transmembrane regions known as helices formed by several AA residues. 
The N-terminus loop from extracellular region continues as helix I and forms an 
intracellular loop which continues further upward as helix II. Thus 7 helices are formed 
spanning between extracellular region and intracellular regions comprising of 3 extra 
cellular loops and 3 intracellular loops excluding the N-terminus loop and C-terminus loop 
which is assumed to be in the intracellular region. Upon examining the x-ray 
crystallographic images of 5-HT1B models using Maestro, helix V continues from the 
transmembrane region to intracellular region then folding further to form 4 additional 
transverse membranes within intracellular region before continuing further upward to 
transmembrane as helix VI. Hence the major part of the intracellular region of the receptor 
is formed by residues from helix V. The intracellular region then further couples with the G 
proteins from the cytoplasmic region. All 5-HTRs are known to form a disulphide bridge 
between residues from ECL2 and helix III. Some 5-HTRs like 5-HT1B are inhibitory in nature, 

















The differences in an active and inactive conformation state of the receptor can aid in 
better understanding the interactions and the subsequent transducer recruitments. 
 
 Understanding active and inactive conformations and the key residues activating the 
trigger motifs or microswitches in 5-HTRs 
 
When we study other resolved active and inactive GPCR conformations such as β2 
adrenergic receptors (β2AR), have demonstrated in the past that certain key residues near 
the binding pocket, upon agonist induced activation, act as trigger motifs or microswitches, 
whereby facilitates large-scale helical rearrangements. Structures of 5-HT1B & 5-HT2B have 
been studied in the past in an active confirmation with ERM ligand. However recently in 
the year 2018 an inactive conformation is known of 5-HT2C in complex with an inverse 
agonist, which reveals some understanding of the biased signalling noticed in the past with 
5-HT2B and the key structural differences that facilitate this phenomenon. Many drugs 
currently researched are actively targeting GPCRs for their involvement in many disorders 
in the past. 5-HTRs are a new addition in the research interests for the treatment of 
various disorders including migraine and resolving the structural details may facilitate drug 
design at multiple GPCRs. A few examples of drugs targeting GPCRs are; opioid analgesics 
targeting μ opioid receptors, anti-histamines targeting histamine H1 receptors, anti-
psychotics targeting DA receptor D2. 
Since this docking experiment used a rigid receptor conformation, to study the 
conformational changes in 5-HT receptor we need to use more dynamic molecular 
modelling system. In the absence of molecular dynamic software tool, superimposing the 
active and inactive conformations of receptors are a great way to study the helical 
relocations upon activation.  
Following residue motifs are important in differentiating an active conformation; 
• PIF motif: Pro, Ile and Phe residues from helices V, III, and VI in β2 adrenergic 
receptors have been shown to rearrange upon activation (58, 78, 83). 
• NPxxY motif: Asn, Pro and Tyr residues involving helix VII of GPCRs (58, 78, 83). 
• DRY motif: Asp, Arg and Tyr residues involving helix III (58, 78, 83, 84).  





The superimposed PIF motifs from 5HT1B and 5-HT2B  when compared to active β2AR 
showed fully active conformations for 5HT1B, however  5-HT2B was indicative of a partially 
acive conformation (57, 59, 78, 82, 85). This difference was thought to be involved in its 
functional selectivity or biased signalling property. This was supported by luminescence 
based assays measuring specific G protein activation (Gi activation & cAMP production) and 
fluorescence based calcium mobilization assays (to measure Gq activation) compared with 
β-AR recruitment measuring assays (β-AR dependent luciferase reporter assays in HEK293 
cell lines) (78). Several mutational studies along with binding kinetics experiments 
conducted in previous researchers have identified the important residues (residues from 
ECL2) involved in 5-HT2B resulting in longer ligand residence with hallucinogenic drugs such 
as LSD in contributing to its hallucinogenic properties, hence this understanding has 
opened new possibilities in structure based drug designs (83).  
3.4 Can anti-migraine drugs be more efficient to improve treatment outcome? 
 
In section 1.3.3 lists the total number of known 5-HTRs, and the complexities involved in 
their signalling mechanisms (section 1.5.4 to 1.5.6). Since the pathogenesis of migraine 
involves the CNS, and the receptor mechanisms involved in migraine is not fully 
understood. The signalling mechanism of 5-HTRs involve subtype selectivity, and both 
inhibitory and agonistic mechanisms involving the diverse receptor subtypes engaging CNS. 
Structural basis for ligand promiscuity and subtype selectivity involving 5-HTRs is still under 
research. 2 distinct receptor conformation specific signalling of 5-HTRs have revealed 
several possible signalling mechanisms involving 5-HTRs. The involvement of DA and NE in 
migraine and the influence of 5-HT in the regulation of the monoaminergic system needs 
to be fully elucidated. 
 
Insilico modelling has helped in understanding the key interactions of ligand receptor 
conformations. Using an active conformation to distinguish the key features in ligand-
receptor recognition process, by comparing a mutated or an inactive receptor 
conformation, has opened more possibilities in structure-based approach using insilico 
modelling studies.  Section 2.3 lists superimposed receptor conformations of two different 
5-HTR subtypes (refer Fig. 2.9 & 2.10), in two distinct active conformations. The extended 





binding pockets were crucial in distinguishing these two receptors, where the binding 
pockets were narrower compared to the other, forcing the ligand to occupy unfavourable 
positions in one of the receptors.  
 
3.5 Conclusions 
An understanding of the receptor characteristics and activation mechanisms may 
ultimately facilitate better drug designs in the future; however, the pathogenesis of 
migraine needs to be fully elucidated to facilitate better drug targeting in the treatment of 
this disorder. A successful drug design should incorporate the diverse pharmacological 
aspects involving agonistic, antagonistic or inverse agonistic activity at the target receptor. 
From the studies discussed in section 1.3.6, it is possible to link DA/5-HT levels in the brain 
to migraine development. 5-HT/DA have affinities to a wide range of receptor subtypes, 
the same could also be true for anti-migraine drugs which may act as neurotransmitters or 
DA/5-HT mimics (due to structural analogy) and possibly be correcting the systemic 
neurotransmitter imbalance by binding to the unoccupied receptors to activate them. 
Therefore, anti-migraine drugs could act as 5-HT or DA mimics. This research thesis has 
indicated this structural analogy clearly via the insilico receptor interaction simulations. To 
test whether these insilico experiments can be reproduced in real systems, in vivo 
experiments (using tissue culture or animal experiments) need to be supported to confirm 
the findings. This research could potentially fill the gaps in our understanding of the 
underlying pathogenesis of migraine and the interactions of anti-migraine drugs with key 
migraine associated neuroreceptors. Thus, this research might help to develop better 
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